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Abstract 
 
Lung cancer is the most common type of cancer worldwide with an exponential growth 
every year. Besides the lately diagnose, lung cancer treatments are often limited to chemother-
apy and radiotherapy, both presenting devastating side effects for the patient. Therefore there is 
a need of developing new ways to fight this problem. Nanotechnology and pulmonary delivery 
have been combined in order to develop pulmonary drug delivery systems that are able to reach 
the deep lung and release a drug into lung cancer cells.  
          Herein we present a new strategy based on the synthesis of strawberry-like gold-coated 
magnetic nanoparticles (Fe@Au NPs) that are later conjugated with micronization technologies 
in order to produce respirable dry powders, nano-in-micro formulations. Once surface modifica-
tions can be easily made by coating the nanoparticle with a fluorescent polymer, the functionali-
zation of these Fe@Au NPs in aqueous media is proposed using a fluorescent oligomer oligo(2-
ethyl-2-oxazoline) endcapped with cysteamine. Fe@Au nanoparticles functionalized with this 
new class of oligomers (OOxs), synthetized in supercritical carbon dioxide (scCO2), were mi-
cronized into polymeric powders in order to produce respirable powders that are able to reach 
the deep lungs. Once in the lung epithelia, the chosen biodegradable and biocompatible carrier, 
chitosan (CHT) is expected to release the nanoformulations in a controlled and sustained man-
ner. The micronization process was achieved using sustainable methodologies that also make 
use of scCO2, the Supercritical Assisted Spray Drying (SASD). The co-atomization of a casting 
solution with CHT and the produced nanoparticles enabled the production of dry powders with 
suitable features for pulmonary delivery. The ability of the engineered nanosystems to degrade 
and release its encapsulated contents was addressed by co-encapsulating the nanoparticles 
with a model drug (ibuprofen). The optimal conditions for the production of the dry powders 
were carefully selected by performing a design of experiment (DoE). With the best conditions 
chosen, two assays were made, one containing the nanoparticles and CHT, and the other con-
taining the nanoparticles, ibuprofen and CHT. Aerodynamic, morphological and physical-
chemical characterizations were assessed. Nanoparticles with diameters ranging from 50-200 
nm and microparticles with diameters of approximately 3 µm were obtained. The produced dry 
powders showed great aerodynamic properties, with fine particle fraction values around 60% 
and mass median aerodynamic diameters around 1.5 µm. An 80% of drug release was 
achieved after 48 hours of study. These preliminary results show that these nano-in-micro for-
mulations could be potential systems to address pulmonary administration of magnetic nanopar-
ticles.  
Keywords: lung cancer, dry powders, supercritical carbon dioxide, nanoparticles, microparti-
cles, supercritical assisted spray-drying, ibuprofen  
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Resumo 
 
O cancro do pulmão é o cancro mais comum a nível mundial com um crescimento ex-
ponencial todos os anos. Para além do diagnóstico tardio, os tratamentos para o cancro do 
pulmão são frequentemente limitados à quimioterapia e radioterapia, ambos com efeitos se-
cundários devastadores para o paciente. Como tal, há uma necessidade de desenvolver novas 
formas de combater este problema. A nanotecnologia e a administração pulmonar têm vindo a 
ser combinadas de maneira a desenvolver sistemas de administração pulmonar de fármacos 
capazes de alcançar o pulmão profundo e libertar o fármaco para as células cancerígenas.  
Aqui, apresentamos uma nova estratégia que tem por base a síntese de nanopartículas 
magnéticas tipo morangos, parcialmente revestidas com ouro (Fe@Au NPs) que serão, mais 
tarde, conjugadas com tecnologias de atomização de maneira a produzir pós secos respiráveis: 
as formulações nano-em-micro. Uma vez que facilmente se pode funcionalizar a superfície das 
nanopartículas Fe@Au NPs em meio aquoso, estas foram revestidas com um polímero fluores-
cente, neste caso um oligómero, oligo(2-etil-2-oxazolina) terminado com cisteamina. As Fe@Au 
NPs funcionalizadas com esta nova classe de oligómeros (OOxs), previamente sintetizados em 
dióxido de carbono supercrítico (scCO2), foram de seguida atomizadas e simultaneamente en-
capsuladas numa matriz de quitosano (CHT) de maneira a produzir pós respiráveis capazes de 
alcançar a zona alveolar do pulmão. Uma vez no epitélio pulmonar, espera-se que o veículo 
biodegradável e biocompatível escolhido, CHT, liberte as nanoformulações de uma maneira 
controlada e continuada. O processo de atomização foi conseguido usando metodologias sus-
tentáveis que também fazem uso do scCO2, a Secagem por Pulverização Assistida por CO2 
Supercrítico. A co-atomização de uma solução modelo com CHT e as NPs produzidas permiti-
ram a produção de pós secos com características adequadas à administração pulmonar. A ca-
pacidade de os nanosistemas produzidos se conseguirem degradar e libertar os conteúdos ne-
les encapsulados, foi estudada ao co-encapsular as nanopartículas com um fármaco modelo 
(ibuprofeno). As condições ideais para a produção dos pós secos foram cuidadosamente esco-
lhidas ao realizar um desenho de experiências (DoE). Com as melhores condições escolhidas, 
dois ensaios foram realizados, um contendo as nanopartículas e o CHT, e outro contendo as 
nanopartículas, o ibuprofeno e o CHT. Os pós produzidos foram caracterizados em detalhe em 
termos da morfologia, propriedades físico-químicas e desempenho aerodinâmico. As nanopar-
tículas apresentaram diâmetros entre os 50-200 nm e as micropartículas diâmetros de aproxi-
madamente 3 µm. Os pós secos produzidos mostraram boas propriedades aerodinâmicas, com 
cerca de 60% de partículas finas e diâmetros aerodinâmicos médios de 1.5 µm. Verificou-se 
que 80% do fármaco se libertou ao fim de 48 horas de estudo. Estes resultados preliminares 
mostram que estas formulações nano-em-micro podem ser sistemas potenciais para usar na 
administração pulmonar de nanopartículas magnéticas.  
Keywords: cancro do pulmão, pós secos, dióxido de carbono supercrítico, nanoparticu-
las, micropartículas, spray-drying assistido por fluidos supercríticos, ibuprofeno  
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Introduction 
Lung diseases are one of the most common medical conditions throughout the world. 
Either caused by environmental pollution, smoking or genetics, lung diseases, such as 
asthma, chronic obstructive pulmonary disease (COPD), chronic bronchitis, cystic fibrosis 
and lung cancer, can have a tremendous impact on peoples’ health leading, most of the 
times, to death.
1,2
 To address these conditions, different systems that can easily carry active 
drugs into the site of action and thus initiate the respective treatments, have been widely in-
vestigated.
2
 A suitable drug carrier or drug delivery system (DDS) should protect the drug 
against degradation, ensuring that the drug attains suitable permeability properties and it is 
carried to the desire site of action. 
3
Therefore, the treatment efficacy mostly depends on the 
techniques by which the drug is delivered (carrier and administration route) and optimum 
concentration of the drug, above or below this range can be toxic or produce no therapeutic 
effect at all.
4,5
 Hence, besides choosing an adequate carrier, it is off extremely importance to 
decide on an adequate route of administration. Due to its simplicity, convenience, and pa-
tient acceptance, oral administration is the most common and preferred drug delivery route. 
However, this route has a risk of drug decomposition by the digestive system, resulting in 
poor and ineffective drug bioavailability. Transdermal drug administration is also simple and 
easy to perform; however drug adsorption is typically inefficient. On the other hand, intrave-
nous (IV) administration results in high adsorption efficiency, which may lead to a toxic blood 
level after injection and sometimes, an under concentration on the desired threshold towards 
the end of the dosing interval. Moreover, it is an invasive method that can create pain at in-
jection sites.
4,6
 In an attempt to circumvent the problems faced by the above-mentioned 
routes, pulmonary administration has been widely investigated once it enables the targeting 
directly to the lung for both local and systemic treatment.
5,7
 In fact, lungs have been widely 
investigated since the ancient times as a route for drug delivery. Egyptians, for instance, 
used to inhale vapors for the treatment of different diseases (1500 BC), and in the middle 
1 
 
2 
 
1920s aqueous nebulizers were used for the treatment of lung infections. However, the use 
of this specific route was forgotten until the year of 1956 with the invention of the first me-
tered dose inhaler (MDI) used in the delivery of albuterol for asthma treatment.
1,2
 There has 
been some developments in this area and dry powder inhalers (DPIs) appeared as an alter-
native to MDI. Since then, pulmonary drug delivery has suffered major advances as an alter-
native to other routes.
8
 
Due to their large surface area, easily permeable membrane, thin absorption mem-
brane (0.1 - 0.2 µm), elevated blood flow (5 L/min), thin alveolar epithelium and extensive 
vascularized alveolar epithelium offering a large absorptive surface (80 – 100 m
2
), lungs can 
easily and rapidly absorb soluble and permeable active compounds.  
Moreover, local treatment is advantageous once there is low enzymatic activity, rela-
tively low local metabolic activity and the drug avoids the first-pass metabolism and is direct-
ly carried into the site of action.
9
 Pulmonary delivery together with controlled release systems 
enables drug protection from rapid degradation or clearance; enhances the accumulation in 
the cells by increasing its bioavailability, therefore lowering the amount of drug required, re-
ducing harmful side effects and reducing costs.
2,10–12
 However, there are some disad-
vantages of pulmonary administration being the most common one the short duration of drug 
action. Therefore, it is necessary to develop controlled release systems for pulmonary ad-
ministration that enable the drug in a controlled and sustained manner to the site of action 
and therefore obtain a more controlled drug action. 
 Polymeric microparticles have been used as drug carriers for controlled delivery sys-
tems. These microparticles were usually regarded simply as carriers and they were not ex-
pected to have any special features besides their suitable sizes for inhalation and dryness. 
Recently, with the wide investigation in the inhalation field, particles’ requirements became 
more complex and the systems should be carefully designed in order to perform specific 
functions such as the transport of the drug, targeted delivery, sustained drug release and 
drug stabilization.
13–15
  
The inhalation technology can be divided into two main areas: i) the development of inhala-
tion devices, through the design of more sophisticated inhalers (though they are complex 
and expensive); and ii) particle engineering, a discipline that assembles the knowledge from 
different areas, such as chemistry, solid state physics, aerosol and powder science. This 
concept is used in the design of particles with suitable characteristics for the different needs 
of the patients.
16
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1.1. Dry powder inhalers  
A good inhaler device should generate an aerosol of a suitable size (1-5 μm), with a 
reproducible drug dosing ensuring that both chemical stability and activity of the drug are 
maintained intact. Also, the device should be simple, easy to use, inexpensive and portable. 
Nebulizers, where the drug is dissolved in a polar liquid, were the first inhalers to be devel-
oped and to appear in the market. Since they were not portable, their use was confined to 
hospitals and homes. Along with this, they also showed some disadvantages, such as low 
efficiency and reproducibility.
2,3,11
 Pressurized metered dose inhalers (pMDIs) were devel-
oped in order to overcome these disadvantages. These new devices not only showed a 
greater efficiency and reproducibility, but they were also easier and faster to use and porta-
ble. However, they required the use of compressed volatile liquids as propellants, (i.e. chlor-
ofluorocarbon and hydrofluoroalkanes), making them environmentally unfriendly and since 
they deliver the dose at high velocity it facilitates the deposition in the oropharynx, which in-
duces local and systemic side effects.
17
 Dry powder inhalers (DPIs) appear in order to over-
come all these problems. Examples of different inhalers are given in Figure 1.1. 
 
 
Figure 1.1 Example of different inhalers a) DPI; b) nebulizer; c) pDMI 
 
 DPIs are also easy to use and portable; however unlike pMDIs they are propellant-
free, making them environmentally friendly. In this case, the aerosols are in a dry state, as-
suring the stability of the drug, therefore there is no need of special storage conditions and 
distribution. However, DPIs are expensive and complex to develop. Most of them have a 
minimum inspiratory effort that is needed for proper use, thus insufficient patient inhalation 
flow rates may lead to reduced dose delivery and incomplete disaggregation of the powder, 
leading to unsatisfactory device performance and subsequently for the break-up of the pow-
der into smaller particles in order to reach the deep lungs, for this reason such DPIs are 
normally used only in older children and adults.
18,19
 Nonetheless, if handled correctly the 
pharmaceutical products used in DPI may result in high local levels of drug in epithelium flu-
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ids of the airways and lower respiratory tract. 
12,18,20,21
 DPIs can be classified as “single-dose” 
devices, which use a single dose capsule; in “multiple unit dose” DPIs, which contains small 
doses separated in several capsules or blisters; and in “multidose” DPIs that contains an 
amount of powder that is then delivered in several metered doses.
21
 A schematic representa-
tion of a person using a DPI is given in Figure 1.2. 
 
Figure 1.2 Schematic representation of (a) a person using an inhaler and (b) a dry 
powder inhaler 
 
1.2. Particle engineering  
There are several different processes for the production of particles. Among these we 
can find milling, spray-drying (SD), spray freeze-drying (SFD) and supercritical fluid assisted 
processes.
22
 Due to the vast thematic regarding the last process, supercritical fluid assisted 
processes are detailed in a subcategory. 
Milling is a method of drug powder micronization and most of the inhalation powders 
are prepared with a jet mill. This process involves micronization by interparticle collision and 
attrition. In sum, the gas passes through a nozzle and particles go into the jet mill where they 
are fractured into smaller ones (while in the gas stream) due to interparticle collisions. The 
path taken by the gas stream allows the exit of fine particles while the larger ones remain in 
the jet mill for further micronization. However, jet milling has lack of control over parameters 
such as size, shape, morphology and surface properties and most of the times, due to the 
high energy required; crystal surfaces are damaged resulting in chemical and physical insta-
bility of the drug.
16,23
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SD is a process that forces a fluid through a nozzle, producing a mist that is dried to 
produce a fine powder. The technique employs a variety of different types of nozzles, some 
of which use ultrasound or air-jet shear to nebulize drug suspensions. SD is very rapid, con-
venient and has very few processing parameters, making it suitable for industrial scalable 
processing and it also provides stability and biological activity for the active pharmaceutical 
ingredient (API). In this process, drug/protein/peptide loaded microspheres are prepared by 
the means of an atomization of the feed solution into a spray, which later enters in contact 
with heated air in a drying chamber forming a dry powder. The nature of the used solvent, 
temperature of the solvent evaporation and feed rate affect the morphology of the micro-
spheres. Unfortunately, this process often utilizes co-solvents to improve drying and/or large 
amounts of excipient to stabilize the drug and to maintain powder properties. Also, there is a 
low adhesion of the microparticles to the inner walls of the spray-dryer, turning the yields 
insufficient, and the possible degradation of heat-sensitive drugs.
16,19,24
 
SPF consists on spraying a solution into a vessel containing a cryogenic liquid such as 
nitrogen, oxygen or argon where the droplets are quickly frozen. Then, these frozen droplets 
are lyophilized resulting in porous spherical particle suitable for inhalation. Yet, there are 
some disadvantages associated with this process, such as the degradation of the products 
from the freezing and drying steps. Like spray drying, loss of stability and aggregation re-
mains a major challenge.
16,24
 
 
1.2.1 Supercritical fluids assisted processes 
Supercritical fluids (SF) are compressed gases or liquids above their critical tempera-
ture and pressure but below the pressure required for solidification to occur. It provides ad-
justable solvent properties based on temperature and pressure and also the possibility of 
operating at mild conditions with reduced use of organic solvents, making this technology an 
alternative to conventional methods for pharmaceutical manufacturing. SFs are widely used 
since they have the density of a liquid, which shows advantageous solvation power, and they 
also have the viscosity of a gas, which confers them a high diffusivity. Since these aspects 
are very changeable near the critical point, it is easy to control both of them by a slightly 
change in pressure/temperature. Also, near the critical point the compressibility and the heat 
capacity are much higher than in other conditions.
25,26
 
The most used SF is carbon dioxide (CO2), since it is nontoxic, nonflammable, has a 
low cost and is readily available in high purity from a variety of sources. This happens since 
CO2 is a subproduct of the industry that can be easily captured and used for other ends. One 
of the main reasons of using CO2 is that, during any process it is possible to separate the 
solvents and residues from the final product by simply reducing the pressure of the system, 
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since CO2 is a gas at normal temperature and pressure, leading to highly pure materials. 
Also, it has a low critical point (31.1
º
C / 73.8 bar)
27
 (Figure 1.3), which is suitable to use with 
heat-sensitive materials and can reduce manufacturing complexity and energy. The only 
constraint facing the use of supercritical carbon dioxide (scCO2) is its limited solvation power 
to polar substances. However, such limitation can be turned into an advantage in a situation 
where it is used as an anti-solvent. Nevertheless, it is possible to modify the solvation power 
by incorporating a small amount of a volatile compound, such as acetone or ethanol.
27,28
 
 
Figure 1.3 Phase diagram of CO2, adapted from M Sihvonen et al.
27
 
 
As stated above, the conventional techniques such as spray-drying have some limita-
tions, especially in the removal of organic solvents. In order to overcome some of these 
problems, alternative particle production methods using SFs, especially scCO2, have been 
proposed.
27
 When using scCO2 the use of organic solvents can be minimized or eliminated. 
This happens due to scCO2 high affinity for those solvents, which enables their removal. A 
rapid expansion of the CO2 using a pressure drop leads to the clustering of CO2 molecules 
inside the liquid polymer, expanding it and inducing pore formation, making the system suit-
able for drug deliver. Moreover, changing operating parameters such as pressure, tempera-
ture and gas release rate can easily alter the morphology and porosity. By changing these 
parameters, we are able to control pore size in the final powders, an important feature that 
increases particles flowability in the respiratory tract.
16,26,29
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SFs have been widely used in particle engineering and it can be divided into three 
methods: precipitation from supercritical solutions composed of SF and solutions; precipita-
tion from gas saturated solutions; and precipitation from saturated solids using SF as anti-
solvent. The first method is based on the solubilization of a drug into scCO2 followed by the 
rapid expansion of the SF solution into a heated hole, causing the reduction of the solution 
density, and therefore decreasing the solvation power of the SF. This will lead to the precipi-
tation of the drug and the process is denominated Rapid Expansion of Supercritical Solution 
(RESS). The second method is similar to the first one since they both involve scCO2 as a 
solvent. However, in this specific process, scCO2 is used as a co-solute and is dissolved in a 
melted solute and the resulting SF solution is fed via an orifice into a chamber, leading to a 
rapid expansion under normal pressure and temperature conditions.
18,22
 This method has 
been called Precipitation from Gas-Saturated Solution (PGSS). The last method is the most 
common one and makes use of the high solubility of scCO2 in organic solvents, which leads 
to a volume expansion when the fluids make contact. Thus, there is a reduction in solvent 
density and in the solvation capacity. Such reduction causes increased level of supersatura-
tion, solute nucleation and particles formation. This method has been assigned different 
names such as Gaseous Anti-solvent (GAS), Aerosol Solvent Extraction System (ASES), 
Solution Enhanced Dispersion by SF (SEDS) and Precipitation by Compressed Anti-solvent 
(PCA).
19,22
 
Recently, Supercritical Fluid Assisted Atomization (SAA) has gained some recognition 
since it shows more advantages over other methods like the ones referred above. This pro-
cess was first described by G. Della Porta et al. 
28
 where supercritical CO2 and a solution of a 
drug (in water or organic solvent) are mixed together and sprayed into a chamber at near 
atmospheric pressure conditions. Then a heated flow of nitrogen enters the chamber to dry 
the particles.
26,30
 In the next subcategory a more detailed explanation is made. 
  
1.2.2. Supercritical assisted spray-drying (SASD) 
Supercritical Assisted Spray-Drying (SASD) is a process similar to the one patented 
by E. Reverchon in US 7276190B2 under the name Process for the production of micro 
and/or nano particles, and is based on the solubilization of controlled quantities of scCO2 in 
liquid solutions. SASD is, in fact, a supercritical assisted atomization, referred in the last 
subcategory, however some conditions were optimized.
31
 The SASD apparatus (Figure 1.4) 
consists in two pumps: one to deliver the liquid solution and another one to deliver the liquid; 
a saturator – the static mixer; a precipitator; a cyclone; and a glass flask. The pumps are 
used to deliver both solutions to the saturator. Since the CO2 pump only pumps liquid solu-
tions, CO2 must be liquefied. Therefore it passes through a cryostat and is then heated 
above its critical temperature. Once it reaches the saturator, the pressure is raised until su-
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percritical conditions. The mixing takes place in static-mixer containing high-surface packing 
that ensures long residence times in order to achieve near-equilibrium conditions.
32
 
 
Figure 1.4 Supercritical Assisted Spray-Drying Apparatus used in this work (real life 
picture). 
 Once all the conditions are met, the solution is expanded through a nozzle (with a 
150.µm diameter) and is atomized by a two-step atomization: the first primary droplets are 
obtained due to pneumatic atomization when exiting the nozzle; then a secondary atomiza-
tion process takes place by decompressive atomization due to CO2 expansion from inside 
the primary droplets, shown in Figure 1.5. This implies that the smallest particle size that can 
be achieved is the size of the smallest droplet achieved during the first atomization. The 
droplet size is determined by viscosity, surface tension and the amount of scCO2 dissolved in 
the liquid solution, while temperature and chemical characteristics of the solute determine 
whether the particles are crystalline or amorphous. SASD offers many advantages over con-
ventional methods, the possibility of operating in a continuous method in mild operating con-
ditions and the ability of using both organic and inorganic solvents while at the same time 
providing a good control over particle size and distribution.
26,32
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Figure 1.5 On the right- image of the spray (real representation); on the left – sche-
matic representation of the atomization process combining the two steps of the atomization 
 
SASD process performance is strictly related to the CO2 solubilization in the liquid so-
lution, which dictates the efficiency of the atomization process. The amount of CO2 solubil-
ized depends on the solvent, temperature, pressure and residence time in the static mixer. 
These parameters are related to high-pressure vapor liquid equilibrium (VLE).
33
 In this work, 
acidic water (1% v/v) and ethanol were the solvents used. The amount of acetic acid in the 
solution is minimal and there is a lack of information in the literature about the solubility of 
acetic acid/water mixtures in CO2, therefore and since there is more information on ethanol-
water-CO2 ternary system, the operating conditions are estimated taking into account the 
VLE ternary system of ethanol-water-CO2.
34,35
 Nevertheless, acetic acid may have some in-
fluence on the VLE, and this should also be taking into consideration. When fixing a deter-
mined pressure and temperature, the mass flow ratio between CO2 and the solvent, we can 
determine the operating point of the ternary system as depicted in Figure 1.6.  
10 
 
 
Figure 1.6 VLE for water-ethanol-CO 2 adapted from C. Duarte et al 
34
. scCO2 
conditions: 31.1ºC / 73.8 bar.  
 
The solubility of CO2 in aqueous solutions is low when working at relatively low pres-
sures and temperatures since the operating point falls in the region of the two-phase gas 
liquid. 
36
 When adding small amounts of ethanol to the solution, and since CO2 has a higher 
affinity to non-polar solvents, the miscibility of scCO2 in water can be improved and process 
efficiency can be increased once the majority of the water mixed with ethanol is taken along 
with CO2.
35,37
 However, the operating point still falls in a two-phase region, so the gas to liq-
uid ratio is not affected. The solubility of scCO2 is also important once it interferes in particles 
production: when dissolved, it reduces the viscosity and surface tension of the solution; 
when non-dissolved, it enhances the pneumatic effect, therefore improving primary atomiza-
tion.
22,35,37
 
Different compounds have already been atomized using SAA technology, such as 
BSA, aluminum sulfate, sodium chloride, among others. In our group, different pulmonary 
excipients have also been atomized, for example cholesterol, CHT, PLGA, leucine and lac-
tose.  
 
1.3. Nanoparticles and pulmonary delivery 
Size and morphology are two main features to be considered in particles design.
18,19
 
Porous particles have both large specific surface area and volume diameter, and show better 
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bioavailability. Moreover, particles targeted to the deep lung, should have a small aerody-
namic diameter (dae) in order to pass through mouth, throat and conducting airways, reach 
the deep lung and avoid macrophage clearance, but not so small that they can not deposit 
and therefore be vented. 
33,38
 Fine particles, the fraction of particles that can reach the lower 
respiratory tract may adhere to the epithelium membrane and can be cleared more 
slowly.
7,39,40
 Particles with larger specific surface area (with porous and with a large volume 
diameter) show better flowability. Therefore, respirable particles, i.e., particles to be respira-
ble, should present aerodynamic diameters in a range of 1–5 µm, when dry. Upon contact 
with an aqueous solution, particles should swell increasing their size and avoiding macro-
phage clearance in the deep lung, as they also provide a controlled and sustained release of 
the drug carried out.
39,41,42
 
Different systems using microparticles have been investigated, such as microparticles 
comprised of one polymer, co-polymers or nanoparticles inside microparticles allowing a bet-
ter control over the drug release.
43,44
 
Recently, nanotechnology has been combined with pulmonary delivery as nanoparticles can 
be used as efficient drug carriers providing a controlled release of the drug entrapped and 
specifically recognizing cellular types.
44–46
 In fact, over the last two decades nanotechnology 
has been providing extraordinary outcomes in both drug delivery and cell targeting. Thus, the 
merging of nanotechnology and pulmonary delivery can bring new improvements for the di-
agnosis and therapy of several types of lung and systemic diseases.
5,47
 Due to their small 
size (1-150 nm), NPs can easily penetrate the deep tissue and be taken up by cells more 
easily while protecting the drugs at both extracellular and intracellular levels. 
48,49
 These 
achievements have been shown to improve drug half-lives and retention, which will substan-
tially decrease unwanted side effects. Besides their therapeutic capabilities, nanoparticles 
can also be designed to exhibit diagnosis features, thus creating theragnosis nanosystems. 
Nanoparticles with theragnosis capabilities can offer many benefits for lung disease patients 
including real time diagnosis, adequate therapy for individual patients (personalized medi-
cine) and reduction of adverse drug effects.
5,47
 
In an attempt to produce theragnosis systems, different types of nanoparticles, such 
as metal (like gold (Au), ferric (Fe) and silver (Ag)) or polymeric, (like Polyethylene-glycol 
(PEG), silica (Si) and poly(lactic-co-glycolic acid) (PLGA)), have been widely investigated.
50
 
The majority of metal NPs have proven to be excellent drug carriers. Also, they are, easily 
functionalized and can be used as active targeting nanocarriers, which is matter of extremely 
importance.
50,51
 NPs lacking functionalization are more likely to interact with plasma proteins 
or uptake my macrophages. By controlling nanoparticles surface properties a stealth charac-
ter can be conferred to the nanosystems, preventing agglomeration and opsonization, there-
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fore protecting them and thus increasing their residence time and ensure the delivery of the 
drug to the desired site of action.
50–52
 
In order to produce reliable theragnosis nanoparticles to use through pulmonary ad-
ministration in a lung cancer condition, a specific type of nanoparticles (strawberry nanopar-
ticles), comprising metallic nanosystems such as magnetic and gold nanoparticles, were fully 
investigated and their features are detailed in the next subsections. 
  
1.3.1 Strawberry-like nanoparticles 
Strawberry-like nanoparticles (SLNs) is a designation given to core-shell nanoparticles 
when the shell is formed by small nanoparticles which are only partially covering the core. 
53
 
This designation is based on the structure and conformation of the nanoparticles because 
since the core is not entirely covered, it is similar to a strawberry and its seeds. SLNs are 
interesting since it is possible to obtain a nanoparticle with different characteristics and prop-
erties that are conferred from both the core and the shell. This happens because, as the core 
is not fully covered, some of its properties and features are able to “flow out” through the 
open areas of the shell and therefore conferring the same characteristics to the whole sys-
tem.
54
 Different types of SLNs can be found, being multifunctional hybrid magnetic nanopar-
ticles (HNPs) constituted of a magnetic core like magnetite (Fe3O4) and a metal shell like 
gold (Au) interesting ones, especially when used for biomedical applications. E. Umut et al, 
have proven that Au–Fe3O4 HNPs have optical activities through Au and can be used as MRI 
contrast agents, meaning that they can exhibit properties from both the components and 
therefore be classified as multifunctional materials.
55,56
 Another important factor for the use 
of the gold shell in this system is that since magnetite nanoparticles are not stable and tend 
to aggregate, the gold shell will confer them some stability, avoiding aggregation, and will 
confer them more biocompatibility as well. 
1.3.1.1 Magnetite nanoparticles  
Superparamagnetic molecules are those that are attracted to a magnetic field but do 
not retain residual magnetism after the field is removed. These nanoparticles are of great 
interest since they have different and fascinating advantages, such as: they can be visual-
ized in magnetic resonance imaging (MRI) due to their paramagnetic properties; they can be 
guided to a location by the use of magnetic field and heated by magnetic field to trigger the 
drug release.
57
  
Magnetite nanoparticles are SPIONs (Superparamagnetic Iron Oxide Nanoparticles) 
that are composed of an iron oxide core. This core can be coated either by inorganic (silica, 
gold) and organic materials (phospholipids, fatty acids, polysaccharides, peptides or other 
surfactants and polymers).
58
 Magnetite NPs features are based on their inducible magnetiza-
13 
 
tion and their magnetic properties, which allow them to be directed to a defined location or 
heated in the presence of an externally applied magnetic field. These features can be ap-
plied in separation techniques and contrast enhancing agents for MRI. Also, they can be 
used as drug delivery systems, for magnetic hyperthermia and magnetically assisted trans-
fection of cells.
59–62
 However, naked particles tend to be very unstable over long periods of 
time and tend to form agglomerates. Therefore, it is important to coat them with a stable ma-
terial, like gold 
63
 Moreover and despite their low toxicity, they can also induce cell damage, 
by forming oxygen reactive species. Some strategies comprising grafting or coating are used 
in order to prevent this toxicity and the possible aggregation. 
63,64
  
 
1.3.1.2 Gold nanoparticles  
Gold nanoparticles (AuNPs) have long been used as delivery systems and recent 
studies have shown the efficiency of this system in lung cancer treatment. 
44,50,65
 Due to its 
advantages, AuNPs can be used as a coating agent in the formation of strawberry-like na-
noparticles. Therefore, by combining the magnetite core with a gold shell we can obtain 
magnetic particles with gold nanoparticles features as well – Fe@Au NP.
62
  
AuNPs optical probes have many advantages due to their inertness and non-toxic 
core, great metal stability, ease of synthesis and surface functionalization, monodispersibility 
and biocompatibility, strong light absorption and scattering effect, high photothermal conver-
sion rate and photostability.
66
 However, colloidal AuNPs easily aggregate especially when 
high salts and certain biological molecules are present. Therefore, the design of functional 
AuNPs must be handled with care in order to assure their properties and stability. In cancer 
research, AuNPs have been studied since it is possible to coat them with fluorescent agents 
capable of targeting to cells and tissues, thus nonspecific toxicity can be minimized and 
transportation efficiency can be enhanced. 
67,68
 However, AuNPs are well known to self-
quench upon surface fluorescent tagging. Therefore it is necessary to come up with a strate-
gy that is able to confer AuNPs fluorescence and at the same time reducing the self-
quenching effect. 
50
 
 
1.3.2. Functionalization of nanoparticles 
Nanoparticles functionalization provides a stealth surface to prevent opsonization, 
therefore increasing their residence time and enhancing therapeutics delivery at the precise 
site of action. Usually, such protection is made by hydrophilic polymers like poly(ethylene 
glycol) (PEG).
69,70
 PEG is the most known and commonly used polymer for conjugation in 
drug delivery. However, some recent reports state that increasing amounts of PEG may lead 
to undesired hepatic accumulation leading to an inflammatory response trigger by the 
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liver.
50,71
 Therefore, poly(2-ethyl-2-oxazoline)-based lipid conjugates have been proposed as 
alternative to PEG-based materials. A. Mero et al.
71
 reported in their work that the properties 
of polyoxazolines-conjugates could be compared with those of similar PEG-conjugates. 
In this work, oxazoline-based polymers are used once they show relatively non-toxicity and 
are generally water soluble and biodegradable.
72
 This kind of materials have been studied 
for many different applications such as smart materials, drug carriers, membrane structures, 
synthetic vectors for DNA and RNA delivery, antimicrobial agents and can also be used for 
nanoparticles protection due to their versatility and ability to form functional materials.
69,72,73
 
Cationic ring-opening polymerization (CROP) is used in the preparation of living polyoxa-
zolines produced in a controlled manner. The term living comes from the fact that at the end 
of the polymerization, the end of the polymeric chain remains active until it is directly termi-
nated.
74
 The synthesis of these oligo(2-oxazoline)s is carried in a high-pressure cell and in 
scCO2. Here, the monomer (a heterocycle) is placed inside the cell and an initiator is added, 
and living CROP occurs.
73
 At the end of the polymerization, and due to incorporation of car-
bamic acid in the oligomer chain during the reaction with scCO2, the final product displays 
fluorescent properties under UV light. In the beginning, the propagating specie is an oxonium 
ion and water must be avoided. Then, once the living polymerization occurs, it is terminated 
by a nucleophilic attack of a heteroatom in the growing polymer chain. In this polymerization 
the final result is a cyclic oligomer that was terminated in an intramolecular way. Initiators are 
strong electrophiles like boron trifluoride etherate.
69,74,75
 The interest in this class of polymers 
is increasing due to their particular characteristics and extensive applications in chemistry, 
biochemistry and pharmacology. 
71,74
 
 Bearing this in mind, in this work oligo(2-oxazoline)s were used to confer nanoparti-
cles fluorescent properties so that they can be tracked using confocal microscopy and to pro-
tect them from opsonization and degradation. 
50
 
In this work, the obtained living oligomer, oligo(2-ethyl-2oxazoline) was later end-
capped with cysteamine, which covalently attaches to the AuNPs shell through the reaction 
between gold atoms and the thiol group of the cysteamine (Au-S). The resulting particles 
were denominated Fe@Au_OEtOx-SH and a scheme illustrating particles formation is given 
in Figure 1.7. 
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Figure 1.7 Schematic representation of the production of the final nanoparticle 
 
1.5 Chitosan as an excipient for pulmonary delivery  
Although the local administration of nanotherapeutics to the lungs may represent the 
best alternative to improve lung cancer, NPs are not in a size that is suitable for deep lung 
delivery as they can be easily exhaled and mucociliary cleared out before reaching the un-
derlying epithelium. 
50
 Therefore the major challenge of pulmonary delivery is to find an ade-
quate carrier system. By using mucoadhesive materials such as CHT it is possible to extend 
the presence of nanoparticles or drugs in the lung epithelium.
76
 
CHT is a cationic linear polysaccharide obtained from the N-deacetylation of chitin 
(Figure 1.8). It is a co-polymer comprising N-acetyl-2-amino-2-deoxy-ᴅ-glucopyranose and 2-
amino-2-deoxy-ᴅ-glucopyranose. Being the second most occurring polysaccharide in nature, 
next to cellulose, and being present in crustaceous shells, chitin is easily used without caus-
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ing much damage to the environment. Several millions of tons of chitin are harvested each 
year as the shell waste of crustaceans, making it a relatively cheap and a readily available 
source.
76,77
 Many applications of CHT have been proposed for both therapy and theragnosis, 
such as for the delivery of therapeutic agents, bioimaging, tissue engineering, wound healing 
and stimuli-responsive materials.
78
 
 
Figure 1.8 CHTstructure, where DA is the degree of N-acetylation Adapted from M. 
Dash et al. 
76
 and J. Kumirska et al. 
79
 
 
For the delivery of therapeutic agents, CHT has been successfully applied to gene de-
livery, growth factor hormones, proteins like bovine serum albumin (BSA), and drugs such as 
ibuprofen, doxorubicin, dopamine and paclitaxel. CHT has already been proved to be biode-
gradable, biocompatible and non-toxic, thus it is an interesting choice to be used as a drug 
carrier, protecting the drug against enzymatic degradation. However, some concerns rely on 
the fact that CHT has not yet been approved by Food and Drug Administration (FDA) for the 
use in pulmonary delivery. In order to be cleared out by the kidneys, CHT should be degrad-
ed by enzymes capable to hydrolyze glucosamine-glucosamine, glucosamine-N-acetyl-
glucosamine and N-acetyl-glucosamine-N-acetyl-glucosamine linkages, such as lysozyme, 
which is also present in the lung mucosa. Moreover, when tested in laboratory mice its LD50 
was found to be similar to sugars and salt. When placed with living samples, CHT-based 
biomaterials show that there are little to no inflammatory or allergic reactions.
76,80
 
When in contact with lungs, the interaction between CHT and lung mucosa is charac-
terized by molecular attractive forces due to electrostatic interactions between positively 
charged CHT and negatively charged mucosal surfaces, promoting drug transmucosal ab-
sorption.
81,82
 Since CHT has a gelling ability when in contact with aqueous solution micropar-
ticles can be used as carriers, the drug is released due to the gelling ability of CHT because 
when it contacts with aqueous solutions, the polymeric chain begins to swell as water enters 
the small holes between each chain. Also, it has recently been confirmed that CHT has a 
drug adsorption-enhancing effect in pulmonary tissues by opening of the intercellular junction 
of the lung epithelium, as well as improving drug targeting and dissolution rate of 
drugs.
76,81,83
 Since CHT is soluble in weak acidic solutions, the production of microparticles 
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offers the possibility of avoiding hazardous organic solvents. Also, CHT has a good ability to 
control the release of active pharmaceutical ingredients (APIs), making it a material of inter-
est to produce and develop drug release systems. Therefore, CHT is here used for pulmo-
nary drug administration, as a biodegradable, biocompatible and non-toxic excipient by pro-
ducing dry powder formulations. The use of dry powders as drug delivery systems has been 
increasingly considered as a treatment option, even though it brings out concerns related to 
respiratory tract anatomy, breathing pattern and particle size. Ideally, dry powders should 
have high dispersibility, drug stability, narrow size distribution and sustained release. Above 
all, there is a need to control both size and morphology of the particles since those are the 
characteristics that affect drug deposition. There is also a need to assure that the particles 
have a physical stability in order to prevent unfavorable solid-state transitions.
81
 
 
1.9 Characterization of particles 
Both the European and US pharmacopeia recommend the use of Andersen Cascade 
Impactor (ACI) and Next Generation Impactor (NGI) when testing inhaling products. 
84
 ACI is 
a sizing sampler containing 8 aluminum stages, each with a collection plate and a filter, and 
an induction port with a suitable mouth piece adapter, operating on the principle of inertial 
impaction. The impaction of a particle is dependent on its aerodynamic diameter, for exam-
ple, if particles have sufficient inertia they will deposit on the first stages of the ACI; if parti-
cles have smaller sizes, they will remain entrained in the air stream and will pass onto the 
next stage. This process is repeated until the last stage of the ACI. Therefore, smaller parti-
cles are collected in the last stages. ACI is presented vertically and each collection plate cor-
responds to a determined cut-off diameter, as seen in Figure 1.9.
84
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Figure 1.9 Collection plates and their corresponding cut-off diameter (µm)for an An-
derson Cascade Impactor with an air flow rate of 60 L/min at a pressure drop of 4 kPa .A – 
schematic representation of an ACI and B – schematic representation seen from inside 
 
All stages have a decrease in the nozzles’ diameter throughout the apparatus. The air-
flow rate should provide a pressure drop of 4 kPa with a defined time that allows the pas-
sage of 4 liters of air through the ACI. 
84,85
 A schematic representation can be seen in Figure 
1.9.  
Particle size is estimated considering the amount of particles collected in each stage 
of the ACI (mass distribution), and can be determined by UV spectroscopy of HPLC.
86
 Fine 
particle fraction (FPF) can also be estimated as being the amount of particles with a cut-off 
diameter bellow 5 µm. An important parameter to take into account is the aerodynamic di-
ameter, which is diameter of spheres with unit density, able to reach the same velocity in the 
air stream as particles of arbitrary shape and density. From this analysis we can also obtain 
another important parameter, the mass median aerodynamic diameter (MMAD), which cor-
responds to the particles’ aerodynamic diameter at 50% of the particle size distribution. It is 
known that particles having a MMAD between 1-5 µm, are easily deposited in the bronchial 
and alveolar regions, especially by sedimentation. These particles have the best pulmonary 
penetration being in the ideal size range for the majority oral inhalation products.
87
 
Another important characteristic of the pharmaceuticals is its solid-state chemistry. For 
lung delivery, the carrier should be amorphous since it shows high dissolution rates, high 
water adsorption and also it is crucial for storage purposes while the API must be crystalline 
so that the bioavailability is maintained.
21
 Nonetheless, and contrarily to crystalline forms, 
19 
 
amorphous compounds are defined by a disorder arrangement of its molecules, showing 
less stability and more reactivity.
21,88
  
Besides the amorphous structure and sizes between 1-5 µm, particles should have 
smooth surfaces and a small contact area, reducing drug adhesion and therefore promoting 
a better drug release and increasing the distance between particles, which will reduce in-
terparticulate forces. All this combined will then lead to a better particle performance.
21,89
 In 
order to address particles’ surface area, a Brunauer – Emmett – Teller (BET) analyses is 
performed. This analysis is based on BET equation is only valid to solid surfaces. Adsorption 
occurs when a fluid gets in contact with a solid surface by interactions between them, involv-
ing two main forces: physical forces (based on small Van der Waals forces) or chemical ad-
sorption (based on chemical bonding between molecules). Although there are six types of 
isotherms, according to IUPAC, herein we describe the Type II sorption isotherm, which can 
be explained by BET equation. 
89,90
 This type is commonly obtained in the case of non or 
macroporous adsorbent, where unrestricted monolayer-multilayer adsorption can occur. An 
inflection point on the isotherm indicates the phase at which the monolayer adsorption is 
complete, and multilayer adsorption begins. In addition to these characteristics, particles 
presenting low relative humidity (˂ 50%) show insignificant capillary forces, however parti-
cles with higher relative humidity present strong capillary forces and therefore higher adhe-
sion forces between the drug and the carrier.
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In order to provide a sustained controlled release, drug-polymer systems were pro-
duced and because of that the release of the drug is dependent not only in the diffusion rate 
from the non-degraded polymer, but also by its swelling and erosion.
91,92
 There are two dif-
ferent phases during particles swelling: a glassy polymer phase and a rubbery-solvent 
phase. When there is no water penetrating the system, the relaxation does not occur and the 
drug is released by Fickian diffusion through the glassy polymer. However, if water can in-
deed enter the polymeric matrix, a “Case-II transport” occurs, which means that we are in the 
presence of a sharp advancing interface at constant velocity, resulting in a zero-order drug 
release. Most of the times, these two mechanisms occur at the same time, providing an 
“anomalous transport”. This is due to the fact that both relaxation and diffusion transport oc-
cur.
91,92
 
When it comes to model the drug release out of polymeric matrices, the Korsmeyer-
Peppas equation (equation 1) has been the most used one to study the diffusional exponent, 
n, which indicates the transport mechanism. The mechanism can either be due to the Fickian 
diffusional release (n=0.43) or polymer’s swelling (n=0.85). It also considers a k that is a  
of the macromolecular network system of the drug. However, it is only valid to the first 
60% of the release, because the further release is dependent on other factors that are not 
taken into account, such as particles degradation.
93
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𝑀𝑡
𝑀∞
= 𝑘. 𝑡𝑛    (1) 
 
1.10 Work thematic 
In the present work, a system combining strawberry-like gold coated magnetite nano-
particles encapsulated into CHT were developed. Dry powders of the nano-in-micro formula-
tions were produced using SASD apparatus. The powders were characterized in terms of 
morphology, physical-chemical and solid state properties and in terms of aerodynamic per-
formance. Also, in order to assess the releasing profile of nanoparticles from the CHT micro-
particles, a release study was performed.  
Since these formulations are supposed to be used as pulmonary drug delivery sys-
tems to fight lung cancer, a model drug was encapsulated and the release profile of the drug 
from the microparticles was also assessed.  
Figure 1.10 shows a schematic representation of the mechanism of action of this sys-
tem. First, the powders should have desired properties for inhalation. Once inhaled, the mi-
croparticles containing the nanoparticles and the drug are supposed to deposit in the deep 
lung region (lung epithelia) and CHT degrades releasing the nanoparticles and the drug. 
Since the nanoparticles are protected with oxazoline, they are protected from degradation. 
The same thing happens to the drug. Once released from the CHT microspheres, nanoparti-
cles undergo an endocytosis process and enter the cancerous cell. Here, they release the 
drug, leading to the death of the lung cancer cell.  
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Figure 1.10 Schematic representation of the mechanism of action of this system 
 
23 
 
Experimental Section 
2.1 Materials  
All components were used as received without any further purification. Chitosan (viscosity 
5-20 mPa.s) was purchased from Tokyo Chemical Industry. Cysteamine (99%) was purchased 
from Sigma Aldrich. Ethanol (EtOH) (96% purity) was purchased in Panreac. Industrial carbon 
dioxide (CO2, purity ≥ 99.93%) was obtained from Air Liquide. The monomer 2-ethyl-2-oxazoline 
(EtOx, ≥ 99% purity), boron trifluoride diethyl etherate (BF3.OEt2), diethyl ether, acetic acid gla-
cial (99.7% purity) hydrogen tetrachloroaurate 99%, sodium citrate 99%, sodium hydroxide, po-
tassium nitrate, sulphuric acid, ferric sulphate, poly-diallyldimethylammonium chloride 
(PDADMAC), poly-sodium styrenesulfonate (PSS) and methanol (MeOH) were purchased from 
Sigma Aldrich.  
 
2.2 Methods  
2.2.1 Synthesis of the strawberry-like gold coated magnetite nanoparticles  
This synthesis was performed following a recent published methodology in the BIO-
SCOPE Lab 308. This methodology included three synthetic steps.
62
 
 
2.2.1.1 Fe2O3 nanoparticles - Fe@SO4
2-  
Fe@SO4
2- 
was synthesized by modifying a method described by M. A. Vergés et al. 
94
  
In this step occurs the precipitation and aging of magnetite nanoparticles. Two different solu-
tions were prepared. A solution (A) containing 90 mL of distilled water, and 90 mL of absolute 
ethanol with NaOH 7x10
-2
 M (12.6 mmol; 0.504g) and KNO3 0.1 M (18 mmol; 1.8384g) was 
placed in a three-necked round bottom flask. A second solution (B) was prepared using 10 mL 
2 
 
24 
 
of distilled water and 10 mL of absolute ethanol containing H2SO4 1x10
-2
 M and Fe(SO4)2 
5x10
-2
 M (1 mmol; 0.2808 g). Both solutions were kept under inert atmosphere separately for 
one hour. Maintaining the nitrogen atmosphere, solution (B) was drop-wise to solution (A). 
When precipitation ended, the nitrogen bubbling was continued for ten minutes. All the reac-
tion mixture was heated at 90 °C for 24 h. 
In the end of the reaction, the round bottom flask was cooled in an ice/water bath. The 
solid magnetic nanoparticles were separated by magnetic decantation and washed five times 
with distilled water. The final magnetic solid was re-suspended in 80 mL of Milli-Q water. 
Strong magnetite nanoparticles with near cube-shaped were obtained. 
 
2.2.1.2 Gold nanoparticles (AuNP)  
First, Au@citrate nanoparticles were prepared in aqueous solution following the-
Turkevich methodology.
95
 An aqueous solution (125 mL) of hydrogen tetrachloroaurate (0.125 
mmol, 49.5 mg) was added rapidly to a solution of 1% (w/v) (0.125 g) sodium citrate (12.5 mL). 
Both the solutions were heated and the addition only occurs when both of them are near the 
boiling point. After mixing them, the heating was maintained for an additional 5 min.  During 
this time, the color changed to deep red.  
 
2.2.1.3 Strawberry-like gold coated magnetite nanoparticles: gold-shell 
formation  
In the third step, following a previous procedure described by Caruso et al.
96–98
 poly-
diallyldimethylammonium chloride (PDADMAC) and poly-sodium 4-styrenesulfonate (PSS) 
were alternately adsorbed onto the negative surface of the magnetic nanoparticles Fe@SO4
2-
. 
A solution of 5 mL of the previous Fe@SO4
2-
synthesized NPs was re-suspended in 100 mL of 
milli-Q water during 2 minutes assisted with ultrasonic energy. 100 mL of a water solution con-
taining 1mg/mL of PDADMAC was added. The solution was maintained in an ultrasonic bath 
during a minute, and under magnetic stirring during two 2 hours. The NPs obtained were sepa-
rated from the supernatant by magnetic separation and washed 10 times with milli-Q water. 
This process was repeated for the adsorption of the PSS layer, and for a second monolayer of 
PDADMAC. 
The three-layer polyelectrolyte magnetite nanoparticles washed previously, were re-
suspended in 100 mL of milli-Q water and mixed with 5 mL of NaCl 0.2 M solution. This solu-
tion was kept during one minute in an ultrasonic bath. After this time, 20 mL of previously syn-
thesized gold nanoparticles was added, and the entire solution was maintained with magnetic 
stirring during 2 hours. The final nanoparticles were separated from the supernatant by mag-
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netic decantation, and washed ten times with milli-Q water being finally re-suspended in 100 
mL of Milli-Q water. 
The formation and growth of the partial gold shell was performed by adding to the solution an 
aliquot of 100 μL of Au
3+
 (5x10
-4
 M) followed by the addition of 100 μL of ascorbic acid 
(0.34x10
3
 M) under ultrasonic stimulation to help nanoparticle separation during the growth 
process. The strawberry-like nanostructures Fe@Au NPs were separated by magnetic de-
cantation and washed ten times with milli-Q water. Subsequently they were re-suspended in 
20 mL of milli-Q water. 
Samples for TEM were prepared by pipetting a drop of the colloidal dispersion onto an ul-
trathin carbon coated copper grid and allowing the solvent to evaporate. 
 
2.2.1.4 Nanocomposite functionalization with Oligo(2-ethyl-2-oxazoline)s 
terminated with cysteamine 
The Fe@Au NPs were suspended in 10 mL of milliQ water and were placed in a flask re-
action. Under stirring in a US bath was added drop-wise 5 mL of polymer solution in MeOH (5 
mg/mL). NPs were kept under magnetic stirring overnight. Afterwards, the nanoparticles were 
washed in MeOH twice. The final material obtained shows high solubility in MeOH. During re-
peated magnetic cycles of purification, we have observed for the first supernatant a subtle red 
colour, mainly derived a small percentage of gold nuclei released during functionalization. How-
ever, as proved by TEM microscopy, the final nanomaterial obtained possesses the strawberry 
structure with the AuNPs anchored to the surface of the magnetic cores.  
 
2.2.2 Synthesis of the living oligo(2-oxazoline) 
The polymerization was carried out following the procedure described by C. Macedo et 
al.
74
 Thus, 2-ethyl-2-oxazoline monomer and the initiator BF3.OEt2 were both added to a high-
pressure stainless-steel reactor, being the monomer/initiator ratio of [M]/[I] = 1/12 . The reac-
tion was carried under stirring conditions and the reactor cell was placed in a water bath at 
60°C. Carbon dioxide was introduced in the reactor until it reached 160 bar. After 24 hours of 
reaction, a continuous washing process was taken using scCO2 for 1 hour. After the washing 
process was concluded, the pressure was slowly released until the reactor reached room tem-
perature. A viscous foam was obtained inside the reactor.
69
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2.2.2.1 End-capping of living oligo(2-ethyl-2-oxazoline)s with cysteamine 
The living oligo(2-ethyl-2-oxazoline) was end-capped with cysteamine, this process is 
performed by adding a tenfold excess of cysteamine (OligoSH) solubilized in anhydrous DMF, 
relatively to the initiator. The mixtures were kept at 70 °C using an oil bath under stirring for 24 
hours. To the oily oligomer solubilized in dry DMF was added diethyl ether and an extraction 
step was performed in order to remove any unreacted oxazoline. This step was repeated four 
times until the diethyl ether phase showed no evidence of impurities. Then, to the aqueous 
phase, a known amount of water was added and the polymer was purified by dialyses against 
pure milliQ water. The resulting mixture was dried under vacuum and the resulting oily polymer 
presented a yellow brownish color with a yield of 6%.
69
 
 
2.2.3 Particle production – SASD apparatus 
SASD apparatus consists on the mixture of scCO2 with a casting solution containing 
CHT and the nanoparticles. Therefore, solutions of 1% (w/v), 2% (w/v) CHT (dissolved in 1% 
acidic water) with and without Ibuprofen and NPs were prepared. All the solutions were atom-
ized and in order to accomplish that, CO2 is liquefied in a cryogenic bath (-20ºC) and pumped 
with a high-pressure liquid pump (HPLC pump K-501, Knauer), which was then heated in an 
oil bath (70°C) and sent to the static mixer (model 37-03-075, Kenics-Chemineer, 4.8 mm ID x 
191 mm L, 27 helical mixing elements). A high-pressure pump (HPLC 305, Gilson) was used 
to pressurize the casting solution into the static mixer, which allows the solubilization of the 
CO2 into the liquid solution due to its high surface packing, promoting the near equilibrium. In 
order to maintain CO2 in its supercritical state (above 73.8 bar and 31 °C),
27
 the static mixer is 
enrolled by heating tapes controlled by a shinko FCS-13A temperature controller (0.2 °C reso-
lution). The pressure in the static mixure is measured using a Setra pressure transducer (0.1 
psig stability). The mixture was then sprayed through a 150 µm diameter pressure nozzle into 
an aluminum precipitator (± 0.1 °C), where the primary droplets are formed, and which oper-
ates at near-atmospheric conditions. At the same time, a continuous compressed heated air 
flow enters into the precipitator and dries the particles by evaporating the liquid solvent and 
promoting the expansion of CO2 from the inside of these primary droplets, originating the sec-
ondary droplets. The compressed air flow is heated before entering the precipitator. The 
formed and dried particles exit the precipitator from the bottom side and enter into a high-
efficiency (Bucchi) cyclone where they are separated from the gas stream and collected in a 
glass flask, placed under the high efficiency cyclone 
32
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2.3 Particles Characterization 
2.3.1 Characterization of nanoparticles 
2.3.1.1 Dynamic light cattering, Zeta Potential and TEM analyses 
The size measurements were performed with the end-capped nanoparticles diluted in 
3mL of methanol in a Zetasizer Nano ZS instrument (Malvern Instruments) in the PROTEO-
MASS facilities. Zeta potential quantification was carried out in the same Zetasizer Nano ZS 
instrument using a zeta dip cell. TEM analysis was performed in Spain, in the University of Vi-
go, CACTI (Center for Researcher and Technical Assistance). 
 
2.3.1.2 UV-Vis spectra and fluorescent analyses 
The UV-Vis spectra of the nanoparticles herein developed were acquired using Perkin 
Elmer Lambda 25 UV/Vis Spectrometer with a slit width of 5 nm at a scan rate of 240 nm min
-1
 
at 25 ºC, in a wavelength range from 350 to 750 nm, and then analyzed with PerkinElmer UV 
WinLab™ software. Fluorescence assays were also performed on a PerkinElmer LS 45 Lumi-
nescence Spectrometer with a slit width of 5 nm at a scan rate of 240 nm min
-1
 using a 10 mm 
path quartz cell and analyzed using FL WinLab™ software. The excitation wavelength was 
fixed at 300 nm.
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2.3.1.3 FT-IR Spectra and 1H NMR 
The 
1
H NMR spectra of the oligo(2-oxazoline) terminated with cysteamine (OEtOxSH) 
was acquired in a Bruker ARX 400 spectrometer. CHT, Fe@Au_OEtOxSH and 
CHT_Fe@Au_OEtOxSH were also analyzed in a Fourier transform infrared (FT-IR) with a reso-
lution of 1 cm
-1
 and 16 scans per sample on a Tensor 27 FTIR (Bruker) coupled with Opus 
Spectroscopy Software. 
 
2.3.2 Characterization of microparticles 
 
2.3.2.1 Morphologi G3 and SEM analyzes 
Particle size analysis was performed by a particle analyzer system (Morphologi G3 Es-
sentials, from Malvern Instruments Ltd). The particles were characterized by the volume mean 
diameter (Dv) and the relative width of the distribution, span, calculated as follows:  
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Span =
Dv,90−Dv,10
Dv,50
        (2) 
 
where Dv,90, Dv,10 and Dv,50 are the diameters at 90%, 10% and 50% cumulative volume. 
Microparticles morphology was determined via Scanning Electron Microscopy (SEM) (Hitachi, 
S-2400 instrument) with an accelerating voltage set to 15 kV and magnifications of 500 and 10k. 
All the samples were mounted on aluminum stubs using carbon tape and were gold-coated pri-
ori analysis. Tapped density of microparticles was determined by compressing a known mass of 
powder in a volumetric container, and measuring the final volume. 
46
 
 
2.3.2.2 FT-IR Spectra, XRD and BET Analyses 
FT-IR was performed in order to study the interactions between CHT and the NP. The 
FT-IR spectra of the materials was done using potassium bromide (KBr) tablets (1% w/w of 
powder in KBr) with a resolution of 1 cm
-1
 and 16 scans per sample on a Tensor 27 FT-IR 
(Bruker) coupled with Opus Spectroscopy Software. 
In order to determine whether the particles were crystalline or amorphous, samples of 
powders were subjected to X-ray diffraction (XRD) analysis (RIGAKU X-ray diffractometer, 
model Miniflex II). Samples were placed in a holder and analyzed through CuKα radiation (30 
KV/15 mA), with a 2θ angle ranging between 2° and 55° with a scan rate of 1°/min.  
BET specific surface area was determined in a Micromeritics ASAP 2010 Physisorption 
Analyser, using 50 mg samples. The analysis was performed in two phases, first by heating the 
sample up to 320 K for 42 h, in order to release all adsorbed gases in the particle. Secondly, the 
temperature was lowered and maintained at 77.35 K during the time of the analysis. 
 
2.3.2.3 Karl Fischer coulometric titration 
Water content of each sample was accessed using Karl Fischer coulometric titration. 1.5 
mg of each sample was placed into the titration vessel and titrated with Karl Fischer reagent, 
which reacts quantitatively and selectively with water. The instrument was composed by the 831 
KF Coulometer and a 728 stirrer Metrohm and by a Pt /-20 -70 °C electrode. 
 
2.3.2.4 Aerodynamic performance of the produced nano-in-micro formula-
tions 32,99 
Andersen Cascade Impactor (ACI) equipment was used to measure the median aerody-
namic particle size, which is seen as a function of density and viscosity as well as the physical 
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dimensions and shape of the particles under development. Such parameter is important since it 
helps to explain how particles behave in a moving air stream (as exemplified by the respiratory 
tract) as opposed to simple “geometric” size. The eight stages of the Andersen Cascade Im-
pactor (ACI) were used to determine the emitted fraction (EF) and respirable fraction (RF) of the 
microparticle powders. The capsule was punctured prior to inhalation and a pump was actuated 
to simulate an inspiration (air flow rate of 62.9 L/min during 3.9 s). Three capsules were emptied 
sequentially for each run. The EF corresponding to the percentage of total loaded powder mass 
exiting the capsules was determined gravimetrically and can be expressed as the emitted frac-
tion (EF%) corresponding to the total loaded powder exiting the capsule, and was calculated as 
follows:  
EF(%) =
mfull−mempty
mpowder
 x 100  (3) 
 
where full and empty are the weights (mg) of the capsule before and after simulating the 
inhalation and powder is the initial weight (mg) of the powder in the capsule. 
The amount of particles entering our respiratory tract (respirable fraction) was calculated by 
subtracting the amount of the particles trapped inside the capsules to the amount of particles 
trapped inside the induction port.  
Fine particle fraction (FPF) was determined by the interpolation of the amount of particles 
(in percentage) with a diameter bellow 5 μm emitted from the capsules in each experiment. 
Mass median aerodynamic diameter (MMAD) was calculated as the particle diameter corre-
sponding to 50% the cumulative distribution. Geometric standard deviation (GSD) was deter-
mined considering the d84 and d16 measures, which are the diameters corresponding to 84% 
and 16% of the cumulative distribution, respectively, and can be calculated by the following 
equation:  
 
GSD =  √
d84
d16
      (4) 
 
 
2.3.2.5 Entrapment Efficiency 
The drug encapsulation was determined by milling a fixed amount of co-atomized pow-
ders and then adding a known amount of PBS. The solution was agitated for 2 h and then was 
centrifuged at 15 000 rpm for 5 min. The supernatant was then collected and the amount of 
drug was determined by UV spectroscopy at 225 nm for IBP. In order to know the entrapment 
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efficiency of the nanoparticles into the CHT microparticles, a sample of 20mg of powder was 
resuspended in aqua regia and the amount of gold and iron was measured through ICP analy-
sis. The encapsulation (E%) was determined by:  
𝐸% =  
𝑚𝑟
𝑚𝑖
 𝑥 100   (5) 
where mr is the remained mass and mi is the initially uploaded mass. 
 
2.3.2.6 In vitro Cumulative Release studies 92,100 
To evaluate the percentage of nanoparticles and IBP that were released from the micro-
particles, 20 mg of the CHT_Fe@Au_OEtOxSH and CHT_Fe@Au_OEtOxSH_IBP powders 
were transferred into a snake skin membrane with a cut size of 1μm and incubated into 5mL of 
different pHs solutions in a shaking bath (36 rpm and 37ºC): 7.4 and 6.8, pH of an healthy cell 
and pH of a cancer cell, respectively. At different time intervals, 1mL of each solution was taken 
and another mL of fresh solution was placed. The absorbance from each sample was read us-
ing a UV-Vis spectrophotometer (225 nm in the case of IBP). This way it is possible to know the 
amount of IBP released from the microparticles. The release profile was adjusted to Korsmeyer-
Peppas mathematical model and the n-value was obtained from the slope of the Korsmeyer-
Peppas plot and represents different release mechanisms. For spherical geometries: n = 0.43 
for Fickian diffusion; 0.43 < n < 0.85 for anomalous non-Fickian diffusion; n = 0.85 for Case-II 
transport. In both cases herein described we have obtained a non-Fickian diffusion, since n = 
0.59 for pH 7.4 and n = 0.61 for pH 6.4.  
Another study was carried: two samples of CHT_Fe@Au_OEtOxSH powder were trans-
ferred to a snake skin membrane and were placed in 5mL of pH 7.4 and pH 6.8. Both the solu-
tions were placed on top of a magnet and after 5 hours and 24 hours a photo was taken. This 
study enables to understand if, upon nanoparticles release from the micropowders, their mag-
netism is maintained. 
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Results and Discussion 
3.1 Nanoparticles Characterization 
All nanoparticles have been characterized in terms of their size and zeta potential. These 
characterizations are important since nanoparticles should not exhibit sizes larger than 150 
nm.
42
 Notwithstanding, particles comprising sizes ranging between 20 to 50 nm have shown to 
have higher cellular internalization.
43,101
 It has also been proved that nanoparticles with non-
cationic surface charge are used in pulmonary delivery since they can be rapidly translocated 
from the lung epithelium to mediastinal lymph nodes. This should provide high levels of drug to 
pulmonary lymph nodes, which could be used to deliver antibiotics and anti-inflammatory drugs 
to treat other lung infections, tumor metastases and inflammatory conditions.
44
 Therefore it is 
important to study the size and potential of the produced nanoparticles. Size measurements are 
not viable in this type of nanoparticles once they tend to agglomerate in solution, therefore con-
ferring low viability during the measurements. Zeta Potential was measured in each step of the 
procedure. The first measurement was performed to the initial nanoparticles without any poly-
meric layer showing a negative potential. Then, after the first addition of the first polymeric layer 
(positively charged polymer) the zeta potential turned positive, proving that the first layer was 
coating the Fe nanoparticles. The same was done for the second layer (negatively charged pol-
ymer) and for the third (positively charged polymer) and zeta turned negative and then positive 
again. The final nanoparticles composed of the magnetite nanoparticles, the three polymeric 
layers, the gold shell and the coating with the oxazoline showed a positive potential, of around 
33.6 mV (Figure 3.11). Having a positive potential at the surface, nanoparticles are supposed to 
be easily internalized since the phospholipidic membrane is negatively charged. Colloidal dis-
persion stability is well dependent they depend on their zeta potential. For values ranging be-
tween +- 30 to +- 40 mV there is a moderate stability, on the other hand values ranging from +- 
10 to +- 30 mV may result in some particle’s instability which may result in some particle aggre-
gation Their sizes are well-suited for delivery into tumoral microenvironments As seen, TEM 
3 
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images (Figure 3.12) were analyzed with JImage® and the average size of the nanoparticles is 
around 100 nm. As a proof-of-concept, this system proves to have the ideal conditions for cell 
internalization.  
 
 
Figure 3.11 Zeta potential of the different layers, where the 4
th
 layer corresponds to the 
final nanoparticles 
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Figure 3.12 Transmission Electron Microscopy images of strawberry Fe/Au nanomaterial 
functionalized with oligo(2-ethyl-2-oxazoline)s in different magnifications. A and B – magnetite 
nanoparticles; C, D, E, F and G – Strawberry-like gold magnetite nanoparticles functionalized 
with oligo(2-oxazoline) 
 
UV-Vis and fluorescent assays were performed in order to corroborate that the oligo(2-
ethyl-2-oxazoline) terminated with cysteamine was, in fact, bonded to the surface of the nano-
particle. Since magnetite gold-coated nanoparticles do not present any fluorescence, then, as 
we add a fluorescent polymer it is expected to observe the presence of an emission band. This 
band can be observed in Figure 3.13, where the emission and the absorption of the final nano-
particles are compared. 
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Figure 3.13 Fluorescence vs Absorbance of the final nanoparticles. The emission band 
can be denoted at 384 nm (orange line) and the absorption band can be seen at 300 nm (blue 
line). 
3.2 Design of Experience: CHT and CHT_Ibuprofen  
In order to evaluate which were the best conditions to operate when producing the micro-
particles, and since a preliminary study proved that microparticles did not change their charac-
teristics by adding nanoparticles, a DoE was performed for the CHT formulations and CHT_IBP 
formulations. In each assay three conditions were changed: pressure in the static mixer (1300 - 
1600 psi); CHT concentration (1% - 2% (w/v)); and solution flow rate (2 – 5 mL/min). In order to 
perform these experiments, a cube was designed and each vertex corresponds to an assay and 
can be observed in Figure 3.12. 
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Figure 3.14 Design of Experiment for CHT and CHT_IBP assays 
 
All the powders obtained in each assay were characterized via ACI analysis and the best 
formulation was chosen concerning the FPF, EF, MMAD, Dv50 and yield. The following Tables 
present the conditions of each assay (Table 1) and the characterizations performed (Table 2 
and Table 3).  
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Table 1 Operating conditions for DoE CHT assays  
Assay 
P 
static mixer 
(psi) 
Solid  
Concentration 
(% w/v) 
Qsolution 
(ml/min) 
QCO2 
(ml/min) 
Qair 
(kg/h) 
Tair 
(in) 
(°C) 
Tair 
(out) 
(°C) 
TCO2 
(°C) 
Tcryostate 
(°C) 
Tstatic 
mixer 
(°C) 
1 1300 1 2 25 22 109.5 76.5 90 -20 80 
2 1300 1 5 25 22 109.5 70 90 -20 80 
3 1300 2 2 25 22 109.5 70.4 104 -20 80 
4 1300 2 5 25 22 109.5 68.9 85 -20 80 
5 1600 1 5 25 22 109.5 67.8 91 -20 80 
6 1600 2 5 25 22 109.5 70.9 79 -20 80 
7 1600 2 2 25 22 109.5 71.4 80 -20 80 
8 1600 1 2 25 22 109.5 75.2 90 -20 80 
9 1300 1.5 3.5 25 22 109.5 67.9 92 -20 80 
10 1600 1.5 3.5 25 22 109.5 71.4 91 -20 80 
11 1450 1.5 3.5 25 22 109.5 69.9 94 -20 80 
12 1450 1.5 3.5 25 22 109.5 67.1 96 -20 80 
  Q – flow; T - temperature; P – pressure 
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Table 2 Aerodynamic properties of CHT dry powders and yield 
Assay MMAD 
(μm) 
RF 
(%) 
FPF 
(%) 
GSD 
(%) 
EF 
 (%) 
Yield, ɳ 
(%) 
1 0.9 65 42.1 2.4 95.8 51 
2 1.1 71 55.8 2.7 98.5 68 
3 1.0 66 53 2.4 95.7 63 
4 1.4 72.6 53.5 2.6 99 55 
5 1.4 68.5 54.6 2.4 98 88 
6 1.5 78.5 59.1 2.6 99 78 
7 1.1 59.2 45.4 2.7 98.5 66 
8 1.1 55.1 37.9 3.1 98 70 
9 1.3 64.8 51.8 2.8 98 71 
10 1.4 48.6 34.7 2.9 99 74 
11 1.3 59.1 46.2 2.9 98.5 72 
12 1.2 58.2 44.3 2.7 99 73 
MMAD – Mass Median Aerodynamic Diameter; RF – Respirable Fraction; FPF- Fine Particle Fraction; 
GSD – Geometric Standard Deviation; EF – Emitted Fraction 
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Table 3 Morphologi G3 results for the produced CHT powders 
Assay Dv,10    Dv,50 Dv,90 Span 
1 1.9 3.3 6.3 1.3 
2 1.9 3.1 4.6 0.9 
3 2.5 4.3 6.6 0.9 
4 3.6 5.6 9.0 1.0 
5 3.2 4.5 9.1 1.1 
6 2.7 5.8 9.1 1.1 
7 1.5 2.9 4.5 1.1 
8 0.8 1.6 3.6 1.8 
9 2.7 5.7 9.6 1.2 
10 2.9 6.7 10.4 1.1 
11 3.2 7.3 11.6 1.2 
12 2.4 5.0 8.7 1.3 
Dv50 – mean volume diameter; Dv90 and Dv10 – volume diameters at 90 and 10% of the population 
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The deposition of the particles during the different stages of ACI, mimetizing the different 
stages of the lung, can be observed in Figure 3.13.  
 
 
Figure 3.15 Representation of the distribution of CHT powders through the different 
stages of the ACI 
 
As seen in the Tables and in Figure 3.15 (ACI), the best assays obtained, bearing in mind 
the FPF, EF, MMAD, Dv50 and yield were assay 5 and 6. However, once the differences be-
tween them are not significant, the assay chosen to continue with the encapsulation process of 
the nanoparticles into the CHT microparticles was assay 5, once it needs lower doses of CHT. 
By doing this experiment, it was possible to understand that the most influencing parameters in 
this process are both the pressure of the static mixer and the flow rate of the solution. As seen, 
higher pressures and higher flows, originate better powders, with better aerodynamic properties. 
In terms of shape, all the particles were similar, once all the particles had a spherical shape, as 
seen in Figure 3.16.   
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Figure 3.16  Morphologi G3 images of the produced CHT powders 
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The same studies were performed in order to evaluate which were the best conditions for 
CHT_IBP formulations. These studies were also based in the same DoE cube. However, in both 
assays 3 and 7, it was not possible to keep the solution at a flow rate of 2 mL/min. Therefore, an 
adjustment was executed and for these two assays the solution flow rate was established to 3 
mL/min. Also, in assay 3 it was not possible to maintain the pressure of the static mixer around 
1300 psi, therefore the assay was performed at 1400 psi.  
The conditions are presented in Table 4 and the characterizations made are presented in 
Tables 5 and 6.  
 
Table 4 Operating conditions for DoE CHT_IBP assays  
Assay 
P static 
mixer 
(psi) 
Solid  
Concentration 
(% w/v) 
Qsolution 
(ml/min) 
QCO
2
 
(ml/min) 
Qair 
(kg/h) 
Tair 
(in) 
(°C) 
Tair 
(out) 
(°C) 
T 
CO
2
 
(°C) 
Tcryostate 
(°C) 
Tstatic 
mixer 
(°C) 
1 1300 1 2 25 20 111.5 65.5 92 -20 80 
2 1300 1 5 25 20 111.5 72 93 -20 80 
3 1400 2 3 25 20 111.5 73.4 95 -20 80 
4 1300 2 5 25 20 111.5 68 97 -20 80 
5 1600 1 5 25 20 111.5 71.8 93 -20 80 
6 1600 2 5 25 20 111.5 70.9 89 -20 80 
7 1600 2 5 25 20 111.5 73.6 90 -20 80 
8 1600 1 2 25 20 111.5 72.3 90 -20 80 
9 1300 1.5 3.5 25 20 111.5 63.9 95 -20 80 
10 1600 1.5 3.5 25 20 111.5 73.6 97 -20 80 
11 1450 1.5 3.5 25 20 111.5 73.2 96 -20 80 
12 1450 1.5 3.5 25 20 111.5 71.6 98 -20 80 
  
Q – flow; T - temperature; P – pressure 
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Table 5 Aerodynamic properties of the produced CHT_IBP powders  
Assay MMAD 
(μm) 
RF 
(%) 
FPF 
(%) 
GSD 
(%) 
EF 
 (%) 
Yield, ɳ 
(%) 
1 1 79.6 54.5 2.4 98.5 57 
2 1.1 82 56.3 2.8 98.6 64 
3 1.1 75.9 54.5 2.7 97.2 66 
4 1.4 81.7 53.6 2.6 97.5 73 
5 1.1 82 56.4 2.6 99 74 
6 1.5 78.3 50.6 2.5 96.1 75 
7 1.3 72.5 58.4 2.6 94.2 64 
8 1.1 73.4 55.2 2.7 95.7 72 
9 1.3 73.9 53.3 2.6 95 59 
10 1.2 73.8 56.6 2.5 93 70 
11 1.1 74.5 57.8 2.6 95.3 62 
12 1.1 75 56 2.5 94.9 65 
MMAD – Mass Median Aerodynamic Diameter; RF – Respirable Fraction; FPF- Fine Particle Fraction; 
GSD – Geometric Standard Deviation; EF – Emitted Fraction 
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Figure 3.17 Representation of the distribution of CHT_IBP powders through the different 
stages of the ACI 
Table 6 Morphologi G3 results for the produced CHT_IBP powders 
Assay Dv,10 Dv,50 Dv,90 Span 
1 2 3.5 5 0.9 
2 2 3.6 5.4 0.9 
3 3.1 6.7 11.7 1.3 
4 2.3 3.8 5.5 0.8 
5 2 3.4 5.3 1 
6 2.4 4.1 6.1 0.9 
7 1.9 3.5 5.2 1 
8 1.7 3.1 5.4 1.2 
9 1.9 2.9 4.2 0.8 
10 2.1 3.5 4.8 0.8 
11 1.9 3 4.2 0.8 
12 1.7 3.3 4.9 1 
Dv50 – mean volume diameter; Dv90 and Dv10 – volume diameter at 90 and 10% of the population 
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Figure 3.18 Morphologi G3 images of CHT_IBP powders 
 
From the results presented and by analyzing Figure 3.18 and Table 6 it is possible to ob-
serve that assay number 5 has the higher respirable fraction and the higher emitted fraction. In 
terms of FPF the differences between all the assays are not significant, therefore assay 5 condi-
tions were chosen as the best operating conditions. These results are in agreement with CHT 
itself, discussed earlier. However, it is possible to observe a positive difference between CHT 
assays and CHT_IBP assays, which means that IBP improves the powder properties, both aer-
odynamic and morphological.  
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Table 7 Moisture content and morphological chatacterization of assay 5 from both CHT 
and CHT_IBP 
Dv,50 – mean volume diameter; Span – (Dv90 – Dv10)/Dv50 
3. 3 Characterization of the CHT_Fe@Au_OEtOx-SH particles  
After finding the best conditions to perform an assay, two different formulations containing 
the nanoparticles were engineered: one with a model drug, IBP, and another one without the 
model drug, CHT_Fe@Au_OEtOxSH_IBP and CHT_Fe@Au_OEtOx-SH, respectively. 
The particles were produced using a solution containing 1% (w/v) of CHT in 100 mL of 
acidic water and ethanol (60:25). To this solution were added 15 mL (7.311 mg) of the nanopar-
ticles. The particles were characterized in terms of morphology via Morphologi G3 equipment; 
aerodynamic performance, via ACI assays; chemical properties, via FT-IR analysis; solid state, 
via XRD and BET analyses; and moisture content, via Karl Fischer Coulometric Titration meth-
od. The entrapment efficiency (E%) was also calculated in order to understand the amount of 
nanoparticles that were entrapped in the CHT microspheres.  
 
Table 8 – Powders physical characteristics. ND – Not detectable. 
Dv,50 – mean volume diameter; Span – (Dv90 – Dv10)/Dv50 
From Table 8 it is possible to verify that both formulations present a volumetric diameter 
around the 3 µm, which allows these particles to efficiently deposit in the deep lung region. Karl 
Fisher assay allowed the assessment of particles moisture content, which was found to be in 
the range of 11.1 – 11.7 % for the engineered formulations.  This relatively small moisture con-
tent of these particles allowed them to efficiently swell when in contact with the lung mucosa, 
and therefore release both nanoparticles and drug in a controlled and sustained manner.  
The results obtained for BET specific surface area analysis are also shown in Table 8. Howev-
er, due to its heterogeneity it was not possible to measure CHT_Fe@Au_OEtOx-SH pore size 
neither pore volume. 
Sample Dv,50 (um) Span  
Moisture Content 
(%) 
CHT (assay 5) 4.5 1.0 11.1 
CHT_IBP (assay 5) 3.4 1.0 9.7  
Sample Dv,50  
(µm) 
Span Moisture 
Content  
(%) 
Entrapment 
Efficiency (%) 
Surface 
Area  
(m
2
/g) 
Pore 
Volume 
(cm
3
/g) 
Pore 
size 
(nm) 
CHT 
3.5 1.0 11.1 
- 15.6 ± 0.8 4.2 6.3 
CHT_Fe@Au_
OEtOx-SH 
2.9 0.8 11.7 71.7 7.9 ND ND 
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Also, analyzing Morphologi G3 and SEM images, Figures 3.19 and 3.20, respectively, it 
is possible to verify that particles present a spherical shape with smooth to rough surfaces and 
even some distorted spheres.  
 
 
Figure 3.19 Morphologi G3 images of CHT_Fe@Au_OEtOx-SH powders at different 
magnifications: a) 5x, b) 10x, c) 20x, d) 50x.  
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Figure 3.20 SEM images of  A and B – CHT; C and D – CHT_Fe@Au_OEtOx-SH 
 
In order to evaluate particles aerodynamic performance, the ACI analysis was performed. 
Two different assays were performed: one combining the nano-in-micro formulations using a 
magnet in the end of the ACI (stage 6) and another one combining the same formulation, but 
without a magnet. This experiment was performed in order to verify if there were any differences 
when applying a magnetic field. The results are displayed in Table 9 and Figure 3.19.  
 
Table 9 Aerodynamic properties of CHT_Fe@Au_OEtOx-SH powders using a magnet 
and without using a magnet 
Assay 
MMAD 
(μm) 
RF 
(%) 
FPF 
(%) 
GSD 
(%) 
EF 
 (%) 
Yield, ɳ 
(%) 
Magnet 1.2 ± 0.1 82.6 ± 0.5 55.4 ± 2 3.3 ± 0.5 99.4 ± 0.1 38 
No Magnet 1.5 ± 0.1 70.2 ± 0.3  55 ± 2 2.5 ± 0.1 97.5 ± 0.04 38 
MMAD – Mass Median Aerodynamic Diameter; RF – Respirable Fraction; FPF- Fine Particle Fraction; 
GSD – Geometric Standard Deviation; EF – Emitted Fraction 
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Figure 3.21 Representation of the particles distribution (with and without a magnet) 
troughout the different stages of the ACI. I.p stands for induction port. 
 
Figure 3.21 shows that when using a magnet in the end of the ACI, particles have a ten-
dency to deposit more in that stage. This effect can be caused by the applied magnetic field in 
such stage; however, in order to confirm this, more studies should be performed to prove that 
this difference is specifically related to the magnetic field applied and not to other factor.  
An ACI study was also executed to compare if there were any differences between CHT 
microparticles and CHT microparticles with NPs. As already mentioned in the introductory sec-
tion, for microparticles to successfully reach the deep lung, particles should have sizes ranging 
from 1 and 5 μm aerodynamic diameters, to be able to pass through the mouth, throat and con-
ducting airways. If the particles are larger than 5 μm they will be trapped in the upper airways. 
On the other hand, if they are below 1μm they are exhaled and fail to deposit. 
The percentage of particle deposition on each stage of ACI, adapter, capsule and the de-
vice was calculated and the emitted fraction of all formulations was also determined. For all mi-
croparticles, the emitted fraction obtained was above 96 % indicating that almost all of the pow-
der is released from the capsule. In Figure 3.21 it is possible to verify that the majority of the 
powder was lost in the induction port, which simulates the upper airways and in the inhaler. This 
may be due to the formation of turbulent eddies in this zone and the major particles aggregates 
cannot reach further stages, and to static electricity, respectively.  
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Table 10 Aerodynamic properties of CHT and CHT_Fe@Au_OEtOx-SH formulations.  
Assay 
MMAD 
(μm) 
RF 
(%) 
FPF 
(%) 
GSD 
(%) 
EF 
 (%) 
CHT 1.2 ± 0.2 65 ± 2 48 ± 2 3.4 ± 0.3 96.3 ± 0.1 
CHT_Fe@Au_OEtOxSH 1.5 ± 0.1 70.2 ±0.3 55 ± 2 2.5 ± 0.1 97.50 ± 0.04 
MMAD – Mass Median Aerodynamic Diameter; RF – Respirable Fraction; FPF- Fine Particle Fraction; 
GSD – Geometric Standard Deviation; EF – Emitted Fraction 
 
Figure 3.22 Representation of particles distribution throughout the different stages of the 
ACI. 
 
As shown in Table 10, the formulations have different MMAD and FPF; but both are able 
to deposit a large amount of particles in the deep lungs. As demonstrated, FPF is improved with 
the addition of the nanoparticles, turning from 49 to 55%, thus these powders have a substantial 
mass fraction of particles below 5 μm, able to reach the deep lungs. 
Fe@Au nanoparticles formulations into CHT microspheres appear to influence the aero-
dynamic performance of the microparticles. The percentage of particles reaching the latest 
stages of ACI is higher when adding nanoparticles than CHT alone. The improved aerodynamic 
performance of formulations comprising Fe@Au NPs might be due to their higher stability and 
lower surface energy. 
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Figure 3.23 FT-IR spectra of the nanoparticles and CHT formulations 
 
Analysing Figure 3.23 there are some characteristic bands of OEtOx-SH polymer and 
CHT powders. Around the 3500 cm
-1
 it is possible to see a O-H stretch from the polymer (a – 
3436 cm
-1
) and from CHT (g – 3415 cm
-1
); at ≈ 2900 cm
-1
, the characteristic band of C-H 
stretches (b – 2923 cm
-1
 and h – 2894 cm
-1
); Et(C=O)N stretch from OEtOX-SH can be found 
around 1700 cm
-1
 (c – 1715 cm
-1
 and d – 1693 cm
-1
);at approximately 1000 cm
-1
 it is possible 
to see  a C-N stretch of the tertiary amine from Au_OEtOx-SH bonding (f – 1069 cm
-1
) and a C-
O stretch of CHT structure (k – 1076 cm
-1
) ; between 1600 and 1650 cm
-1
 an N-H bend from the 
amine groups of CHT is found (i – 1645 cm
-1
); C-H bend from CH3 is found at 1400 cm-1, either 
from OEtOx-SH and CHT (e – 1406 cm
-1
 and j – 1409 cm
-1
).  
 
Also, it is possible to understand that due to the high amount of CHT in relation to the 
amount of nanoparticles, there are no significant changes between CHT and 
CHT_Fe@Au_OEtOx-SH formulations.  
The XRD patterns of CHT and CHT_Fe@Au_OEtOxSH are displayed in Figure 3.24. 
Both formulations only exhibit the amorphous state of processed CHT (broadening at 2 =20º). 
IBP XRD pattern has already been analyzed in the literature revealing the presence of sharp 
peaks, confirming its crystalline structure.
32,102
 Likewise, magnetic nanoparticles are also de-
scribed in the literature as crystalline nanoparticles.
103,104
 Upon co-atomization with CHT, no 
crystalline peaks are denoted, corroborating that our particles are fully entrapped in the CHT 
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matrix. Such amorphous excipients are able to stabilize the active pharmaceutical ingredient 
(API), increasing the dissolution rate. Moreover, these excipients show a high water adsorption 
capacity, contributing for a sustained release and a fast cellular absorption. The API, on the 
other hand, should be in a crystalline form in order to maintain its bioavailability, maximizing its 
efficiency and reducing the required dosage. 
18
 
 
Figure 3.24 XRD pattern of CHT and CHT_Fe@Au_OEtOx_SH 
 
To study the release of the nanoparticles from the microspheres, two release studies 
were performed to evaluate the release profile. Both studies were carried in two different pHs, 
mimmetizing the conditions of a healthy lung (pH 7.4) and a cancerous lung (pH 6.8). The first 
one was set in order to study if there was any magnetism when the nanoparticles were released 
from CHT. For this, a magnet was placed under both solutions and the photos were acquired.  
52 
 
 
Figure 3.25 - Release study of the nanoparticles from the microparticles using a magnet. 
Figure on the left shows the flasks containing the powders in different pH solutions. 
  
It is possible to observe a small black dot in the solution of pH 6.8 (Figure 3.25), exactly where 
the magnet was located. This is indicative that when released from CHT, nanoparticles still 
maintain their magnetism, which allows them to deposit in a place where a magnetic field is be-
ing applied. These results demonstrate, as a proof-of-concept the feasibility to encapsulate 
magnetic nanoparticles for inhalation. However, further studies should be performed in order to 
understand the ideal force of an induced magnetic field that need to be applied in a real situa-
tion.   
 
3.4 Characterization of CHT_Fe@Au_OEtOxSH_IBP particles 
To the already known system of CHT_Fe@Au_OEtOxSH particles, a model drug was at-
tached in order to see if there were any significant changes in terms of morphological and aero-
dynamic properties. Also, this model drug was encapsulated to evaluate this system in terms of 
controlled release. Therefore, an in vitro cumulative release study was performed, and this was 
adjusted to the Korshmeyer-Peppas mathematical model. Solutions containing 1% (w/v) of CHT 
in a volume of 100 mL (60% acidic water, 25% Ethanol and 15% NPs solution) were prepared 
and then 100 mg of Ibuprofen was added. 
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Table 11 Physical properties of CHT_Fe@Au_OEtOxSH_IBP particles 
Dv,50 – mean volume diameter; Span – (Dv90 – Dv10)/Dv50 
 
Figure 3.26 Morphologi G3 images of CHT_Fe@Au_OEtOx-SH_IBP formulations 
 
ACI results of the solutions with Ibuprofen are presented in Table 12. As seen, and com-
paring with the results displayed in the last section, the addition of IBP to CHT microparticles 
and the addition to CHT_Fe@Au_OEtOxSH microparticles, have improved both FPF and EF 
results. When comparing CHT with CHT_IBP, a significant change in FPF is visible, once it 
changes from 49 to 54%. The same happened to the amount of respirable particles (RF) which 
is also increased by the addition of IBP: from 65 to 72% in the case of CHT, and from 70 to 75% 
in the case of CHT_Fe@Au_OEtOxSH. When comparing the EF in both cases, it is possible to 
observe, as well, an increment of the values when adding IBP. In the case of CHT and 
CHT_IBP, EF changes from 96.3 to 97.5%.  
Sample 
Dv,50  
(um) 
Span Moisture 
Content  
(%) 
Entrapment 
Efficiency 
(%) 
CHT_Fe@Au_OEtOXSH_IBP 3.127 0.98 10 68.33 
54 
 
By analyzing the data it is possible to conclude that IBP confers greater aerodynamic 
properties to this system, indicating that by attaching a drug to it, the aerodynamic conditions 
are not negatively affected and proving that it can be used as a drug delivery system.  
 
Table 12 Aerodynamic properties of CHT_Fe@Au_OEtOx-SH_IBP formulation 
Assay 
MMAD 
(μm) 
RF 
(%) 
FPF 
(%) 
GSD 
(%) 
EF 
 (%) 
CHT_IBP 1.3 ± 0.2 72.1 ± 2.8 53.5 ± 2.8 1.9 ± 0.1 97.5 ± 0.8 
CHT_Fe@Au_OEtOxSH
_IBP 
1 ± 0.1 74.8 ± 2 55.8 ± 1.2 2.5 ± 0.1 98.7 ± 0.2 
MMAD – Mass Median Aerodynamic Diameter; RF – Respirable Fraction; FPF- Fine Particle Fraction; 
GSD – Geometric Standard Deviation; EF – Emitted Fraction 
By comparing only CHT_IBP to CHT_Fe@Au_OEtOxSH_IBP it is possible to observe 
that all the values are very similar. Thus, the changes analyzed above are most certainly due to 
the addition of IBP and not to the addition of NPs. As seen in Figure 3.27 both the formulations 
of CHT_IBP and CHT_Fe@Au_OEtOxSH_IBP are able to reach the final stages of the ACI, 
indicating that these formulations are also able to deposit in the deep lung region. Also, particles 
tend to accumulate in the inhaler and in the induction port, this is also justified by the static elec-
tricity and by the formation of turbulent eddies in the upper airways (induction port).  
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Figure 3.27 Representation of particle distribution  throughout the different stages of the 
ACI  
 
To evaluate the release profile of IBP from the nano-in-micro formulations, a study was 
carried in two different pHs, mimetizing the conditions of a healthy lung (pH 7.4) and a cancer-
ous lung (pH 6.8). As previously mentioned, the release profile was adjusted to Korsmeyer-
Peppas mathematical model.  
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Figure 3.28 A) In vitro cumulative release studies at different pHs; B) Korsmeyer-Peppas 
adjustment for 60% of the release 
Table 13 Korsmeyer-Peppas adjustment values for IBP release 
 n k (h
-1
) % mass released 
pH 7.4 0.6 23.1 68.9 
pH 6.8 0.6 19.2 81.7 
n – diffusional exponent; k – constant 
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As depicted in the Figure 3.28, the release profile of IBP is different in the two pHs. The 
n-value is obtained from the slope of the Korsmeyer-Peppas plot and represents different re-
lease mechanisms. For spherical geometries: n=0.43 for Fickian diffusion; 0.43<n<0.85 for 
anomalous non-Fickian diffusion; n=0.85 for Case-II transport. Therefore, in both cases, the n-
value is 0.6, which means that we are in the presence of a non-Fickian diffusion. Having an 
anomalous transport the release rate has the contribution of both diffusion and relaxational 
mechanisms-stresses during polymer swelling.  
As seen, the amount of released particles is higher at pH 6.8 than pH 7.4. This occurs 
since the pKa of CHT is around 6.5, thus at 6.8 CHT has approximately half of its amino groups 
are protonated turning the matrix more hydrophilic than at pH 7.4 where the amino groups are 
deprotonated. This leads to a faster release of IBP from the CHT particles at pH 6.8 than at 7.4.  
These results also show us that this system is capable of releasing a drug in a controlled man-
ner and that it could easily release IBP in a lung cancer situation (pH 6.8), therefore conferring 
great outcomes for the release of a drug in an unhealthy condition.  
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Conclusions 
In the present work, CHT microparticles containing the functionalized NPs and IBP were 
successfully micronized. These powders exhibit appropriate characteristics, either in terms of 
their size, morphology or aerodynamic properties, all suitable for inhalation. CHT has also 
proved to be a potential candidate to be used as carrier for therapeutic agents in a lung cancer 
situation since it has a higher release percentage at an acidic pH condition (cancerous pH). As 
presented in the introduction, the development of dry powders for inhalation stands as an out-
break solution to overcome drawbacks associated with drug delivery. Herein, we have proved 
that this system is capable to overcome these problems. The fluorescent and magnetic nano-
particles can be used in lung cancer imaging and hyperthermia. However further studies con-
cerning the use of an applied magnetic field should be made in order to prove their efficacy. Alt-
hough we have proven that the final NPs presented fluorescence due to the presence of the 
oligo(2-oxazoline), it is necessary to perform a confocal laser microscopy study to prove their 
effectiveness towards imaging. Also, as demonstrated in the release studies conducted with a 
magnet and from the ACI studies performed with a magnet as well, we have seen that the NPs 
still maintain their magnetism, especially after being released from the microspheres. Therefore, 
in order to understand if this system can be used as imaging, by making use of the magnetic 
core, a magnetic resonance imaging (MRI) experiment should also be assessed. Magnetic hy-
perthermia studies in lung cancer cells are also needed to prove that these NPs are able to kill a 
lung cancer cell by heating and vibrating the nanoparticles.  
Based on their sizes and zeta potential, as well as fluorescent capabilities, the developed 
NPs should be in suitable conditions for appropriate cellular internalization and imaging. In vitro 
cellular experiments should be conducted in order to sustain the theory. If the results are favor-
able, moving to an in vivo scale should be the next step. The idea is to be able to conduct parti-
cles, with the aid of their magnetic field, to an exact location like the cancerous tissue, as seen 
in Figure 4.29.  
4 
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Figure 4.29 Schematic representation of the delivery of a dry powder contain magnetic 
nanoparticles in order to guide them to the desired region(s) of the lung by using of a strong 
external magnetic field. Adapted from M. Dolovich et al. 
105
 
 
Regarding the SASD apparatus, an optimization process was engineered for this project 
in order to increase the recovery yields. Temperatures were increased, improving process 
yields from 20 to 70-80 %. Further optimizations regarding the pressure should also be con-
ducted.  Despite the great increase in the percentage of recovered particles, a significant per-
centage is being lost during the process by leaving with the gas stream. Thus, it is necessary to 
come up with a strategy, like the use of filters, capable of trapping these particles, in the recov-
ery flask. The production of CHT microparticles should also be optimized in order to create less 
aggregated particles. For this, a deeper study (besides DoE) concerning pressures and temper-
atures during the process should be addressed.  
DoE studies enabled us to understand which were the best operating conditions when 
working with formulations containing CHT and CHT with IBP. In both cases, at higher pressures 
and higher flows, the obtained results were improved, either in terms of respirable fractions as 
in terms of fine particle fraction. After choosing the best operating conditions, the assays con-
taining the NPs and IBP were performed. Both the powders presented suitable aerodynamic 
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and morphological characteristics, and the assay containing IBP showed an 80% release during 
48 hours of study. This indicates us that this system is not only able to deposit in the deep lung 
region, but also to release a drug in a controlled manner. Although particles did not show any 
reaction upon the application of a magnetic field, there were slightly changes in the ACI studies 
with and without the magnet. This is indicative that the powders may have magnetism, even if it 
is at a small percentage. To confirm these preliminary results, replicates should be performed in 
order to evaluate its statistical significance. Also, when we performed the release study of the 
NPs with the magnet, it was possible to verify that a small dot of NPs tend to deposit on the 
place where the magnet was. This may lead us to the idea that the NPs actually maintain their 
magnetism, although some of it is lost when covering the nanoparticles with CHT.  
To conclude, the system developed along this project is a possible candidate for pulmo-
nary administration of drugs either for local or systemic theragnosis. Although, as referred earli-
er, these studies are insufficient to determine that this is in fact a viable system, the proof of 
concept studies are satisfactory as it demonstrated the feasibility of the process for the produc-
tion of an adequate drug delivery system for pulmonary use in lung cancer situations.  
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Appendix 
6.1 Absorbances and Fluorescence Assays 
 
 
 
Figure A30 Absorbance at different concentrations of the polymer 
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Figure A31 Calibration curve of the polymer 
 
 
 
Figure A32 Polymer intensities at different concentrations 
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Figure A33 Calibration curve at different polymer concentrations 
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6.2 – NMR spectra of the oligo(2-ethyl-2-oxazoline): 
1
H and 
13
C  
 
Figure A34 
1
H NMR spectrum of the polymer 
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Figure A35 
13
C Spectrum of the polymer
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6.3 – Drug release data  
Table 14 Absorbances and concentrations of the drug release study at pH 6.4 
pH 
6.4 
Absorbances Absorbances corrected Concentration Average In 5 mL 
 
20.6 
mg 
20.9 mg 20.8 mg 20.5 mg 
    
t CHT IBP 1 IBP 2 IBP 3 IBP 1 IBP 2 IBP 3 IBP 1 IBP 2 IBP 3 
 
IBP 1 IBP 2 IBP 3 
0.25 0.186 0.81 0.752 0.427 0.624 0.566 0.241 0.030531 0.027694 0.011792 0.035130639 0.152657 0.138468 0.235835 
0.5 0.179 0.306 0.243 0.601 0.127 0.064 0.422 0.006214 0.003131 0.020648 0.039990867 0.124278 0.062628 0.412956 
0.75 0.175 0.346 0.446 0.521 0.171 0.271 0.346 0.008367 0.01326 0.016929 0.051407509 0.167335 0.265192 0.338585 
0.01
7 
0.176 0.494 0.434 0.577 0.318 0.258 0.401 0.015559 0.012624 0.01962 0.063737482 0.311185 0.252471 0.392406 
1.5 0.154 0.521 0.512 0.692 0.367 0.358 0.538 0.017957 0.017516 0.026324 0.082395538 0.359135 0.350328 0.52647 
2 0.136 0.586 0.588 0.695 0.45 0.452 0.559 0.022018 0.022116 0.027351 0.095312653 0.440356 0.442313 0.54702 
2.5 0.187 0.597 0.623 0.671 0.41 0.436 0.484 0.020061 0.021333 0.023681 0.086766481 0.401213 0.426656 0.473628 
3 0.107 0.529 0.576 0.649 0.422 0.469 0.542 0.020648 0.022947 0.026519 0.09348599 0.412956 0.458949 0.530385 
3.5 0.094 0.521 0.587 0.572 0.427 0.493 0.478 0.020892 0.024122 0.023388 0.091202662 0.417849 0.482435 0.467756 
4 0.096 0.614 0.68 0.586 0.518 0.584 0.49 0.025345 0.028574 0.023975 0.103858825 0.506899 0.571484 0.479499 
5 0.091 0.581 0.643 0.515 0.49 0.552 0.424 0.023975 0.027009 0.020746 0.095638843 0.479499 0.54017 0.414913 
6 0.111 0.465 0.545 0.429 0.354 0.434 0.318 0.017321 0.021235 0.015559 0.072153179 0.346414 0.424699 0.311185 
7 0.085 0.478 0.475 0.363 0.393 0.39 0.278 0.019229 0.019082 0.013602 0.069217471 0.384578 0.381642 0.272042 
8 0.099 0.369 0.424 0.305 0.27 0.325 0.206 0.013211 0.015902 0.010079 0.052255602 0.264214 0.318035 0.201585 
9 0.132 0.368 0.382 0.209 0.236 0.25 0.077 0.011547 0.012232 0.003767 0.036728969 0.230942 0.244642 0.07535 
24 0.21 0.348 0.378 0.215 0.138 0.168 0.005 0.006752 0.00822 0.000245 0.020289004 0.135043 0.1644 0.004893 
48 0.367 0.395 0.39 0.371 0.028 0.023 0.004 0.00137 0.001125 0.000196 0.003588088 0.0274 0.022507 0.003914 
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Table 15 Aborbances and concentrations of the drug relase study at pH 7.4 
pH 7.4 Absorbances Aborbances correctes Concentration Average 
 
In 5 mL 
 
 
20.9 mg 21 mg 20.4 mg 21.2 mg 
    
t CHT IBP 3 IBP 4 IBP 5 IBP 3 IBP 4 IBP 5 IBP 3 IBP 4 IBP 5 
 
IBP 3 IBP 4 IBP 5 
0.25 0.166 0.863 0.681 0.338 0.697 0.515 0.172 0.034103 0.025198 0.008416 0.030988 0.170516 0.125991 0.168314 
0.5 0.172 0.302 0.585 0.282 0.13 0.413 0.11 0.006361 0.020207 0.005382 0.027009 0.095411 0.202075 0.107643 
0.75 0.163 0.247 0.731 0.347 0.084 0.568 0.184 0.00411 0.027791 0.009003 0.034641 0.06165 0.277914 0.180057 
0.017 0.13 0.277 0.972 0.471 0.147 0.842 0.341 0.007192 0.041198 0.016685 0.056904 0.107887 0.411978 0.333692 
1.5 0.148 0.591 0.524 0.475 0.443 0.376 0.327 0.021675 0.018397 0.016 0.067538 0.32513 0.367942 0.319992 
2 0.144 0.562 0.608 0.499 0.418 0.464 0.355 0.020452 0.022703 0.01737 0.073882 0.306781 0.454056 0.347392 
2.5 0.119 0.588 0.577 0.478 0.469 0.458 0.359 0.022947 0.022409 0.017565 0.076247 0.344212 0.448185 0.351306 
3 0.103 0.609 0.535 0.451 0.506 0.432 0.348 0.024758 0.021137 0.017027 0.075643 0.371367 0.422742 0.340542 
3.5 0.096 0.575 0.474 0.399 0.479 0.378 0.303 0.023437 0.018495 0.014825 0.067864 0.351551 0.369899 0.296507 
4 0.111 0.624 0.553 0.467 0.513 0.442 0.356 0.0251 0.021626 0.017419 0.07716 0.376505 0.432528 0.348371 
5 0.127 0.666 0.586 0.484 0.539 0.459 0.357 0.026372 0.022458 0.017467 0.079607 0.395587 0.449163 0.349349 
6 0.132 0.628 0.527 0.425 0.496 0.395 0.293 0.024269 0.019327 0.014336 0.069152 0.364028 0.386535 0.286721 
7 0.144 0.586 0.458 0.396 0.442 0.314 0.252 0.021626 0.015364 0.01233 0.058551 0.324396 0.307271 0.246599 
8 0.177 0.486 0.436 0.388 0.309 0.259 0.211 0.015119 0.012672 0.010324 0.045781 0.226783 0.253449 0.206478 
9 0.168 0.491 0.366 0.35 0.323 0.198 0.182 0.015804 0.009688 0.008905 0.040594 0.237058 0.193757 0.1781 
24 0.38 0.644 0.425 0.423 0.264 0.045 0.043 0.012917 0.002202 0.002104 0.018658 0.193757 0.044036 0.042078 
48 0.35 0.439 0.427 0.439 0.089 0.077 0.089 0.004355 0.003767 0.004355 0.016636 0.087093 0.07535 0.087093 
 
